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In Eukaryotes, folate-dependent one-carbon (1C) metabolism is a highly 
compartmentalized process in which mitochondria play a central role. Defects in folate 
metabolism are associated with diseases such as cancer, Alzheimer's disease, and neural 
tube defects (NTDs). 1C units are attached to tetrahydrofolate (THF) and carried in 
various oxidation states between folate-dependent enzymes. There is an exchange of 1C 
units across the mitochondrial membrane, with 1C donors such as serine and glycine 
being oxidized to formate in the mitochondria, which is then released into the cytoplasm. 
1C units in the cytoplasm can be used for the synthesis of purines, thymidylate, and 
methionine for the methyl cycle. The core of the pathway in both compartments is 
catalyzed by the methylene-tetrahydrofolate (MTHFD) gene family. These enzymes 
catalyze the reversible interconversion between CH2-THF, CH
+
-THF, CHO-THF, and 
formate. The cytoplasmic protein MTHFD1 is trifunctional and carries the CH2-THF 
dehydrogenase, CH
+
-THF cyclohydrolase, and 10-CHO-THF synthetase activities 
necessary to carry out these interconversions. In the mitochondria, two bifunctional 
isozymes, MTHFD2 and MTHFD2L, carry the dehydrogenase/cyclohydrolase (D/C) 
activities. The monofunctional enzyme MTHFD1L is responsible for the synthetase 
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activity. MTHFD2 is only expressed in embryos and transformed cells, and the enzyme 
responsible for the D/C activity in adults was unknown until the recent discovery of 
MTHFD2L. In this work, characterization of the expression of MTHFD2L in mouse 
embryos and adults is described. Expression of MTHFD2L in embryos was found to be 
switched on between embryonic days 8.5-10.5, and remains high throughout 
development. MTHFD2L is also widely expressed in adults, with highest expression in 
brain and lung. A splice variant of MTHFD2L lacking exon 8 was found to be abundant 
in embryos but was not catalytically active in vitro or in vivo. MTHFD1L is an essential 
protein, and SNPs in MTHFD1L are associated with increased risk for Alzheimer's 
disease and NTDs in humans. Loss of MTHFD1L activity in adult mice with and without 
a folate deficient diet was investigated. Indications of sex-dependent behavioral 
anomalies were found, with evidence for genotype-dependent hyperactivity in male mice 
and diet-dependent anxiety in female mice, but further investigation of these findings is 
warranted. Finally, metabolic defects associated with NTDs and growth restriction in 
MTHFD1L-null (Mthfd1l
z/z
) embryos were identified. Glycolysis, the TCA cycle, and the 
metabolism of methionine, purines, and multiple amino acids were found to be disrupted 
in Mthfd1l
z/z
 embryos. These altered metabolic pathways suggest potential future 
therapies for preventing NTDs in humans. 
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Chapter 1: Introduction 
1.1 FOLATE-DEPENDENT ONE-CARBON METABOLISM 
1.1.1 Cellular Folates 
1.1.1.1 Folate Structure 
"Folates" are a collective group of molecules including folic acid and its reduced 
derivatives which can carry one-carbon (1C) units in one of several oxidation states. 
Folates are composed of a pteridine ring that is covalently linked at carbon 6 to para-
aminobenzoic acid (PABA) with a poly-γ-glutamate tail (Figure 1.1). Tetrahydrofolate 
(THF), as shown in Figure 1, is the active form of folate in mammalian cells. Dietary 
folic acid must first be reduced to THF before it can participate in 1C transfer reactions. 
This reduction is carried out in two steps by the enzyme dihydrofolate reductase (DHFR). 
Using NADPH as an electron donor, DHFR first reduces folic acid to 7,8-dihydrofolate 
(DHF), then further reduces DHF to 5,6,7,8-tetrahydrofolate. Within cells, THF typically 
has a poly-γ-glutamate tail consisting of 5-7 glutamate residues. Synthesis of the poly-γ-
glutamate tail is catalyzed by folylpolyglutamate synthetase (FPGS), which attaches 
glutamate residues with an amino-γ-carboxyl bond (Shane, 1989). The glutamate tail is 
essential for retention of folates within a cell (McBurney and Whitmore, 1974; Taylor 
and Hanna, 1977). The exact length of the tail can vary depending on the organism and 
the intracellular compartment. In Chinese hamster ovary (CHO) cells, the heptaglutamate 
form tends to predominate in the mitochondria, while the hexaglutamate form is more 
common in the cytoplasm (Lin et al., 1993). On the other hand, rat liver cells were found 
to have a higher proportion of the pentaglutamate in the mitochondria and hexaglutamate 





Figure 1.1 Structure of tetrahydrofolate. THF is composed of a pteridine ring, a PABA 
moiety, and a poly-γ-glutamate tail. Activated one-carbon units, represented 
by R1 and R2, can be carried at N5, N10, or bridging N5 and N10 in various 
oxidation states (Figure reproduced from (Tibbetts and Appling, 2010)).   
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THF can carry 1C units at either N5 on the pteridine ring, N10 on the PABA 
moiety (R1 and R2 respectively in Figure 1), or as a single carbon bonded between N5 
and N10. The most common forms of folate include 5-methyl-THF (CH3-THF), 5,10-
methylene-THF (CH2-THF), 5,10-methenyl-THF (CH
+
-THF), 10-formyl-THF (10-CHO-
THF), and 5-formyl-THF (5-CHO-THF). The exact distribution of these cofactors is 
dependent on the subcellular compartment in which they are found. In rat liver 
mitochondria, the 10-CHO-THF and THF forms predominate, making up 33.1% and 
48.1% of the folate pool, respectively. The folate pool in the cytoplasm is composed 
primarily of THF (27%), 5-CH3-THF (45%), and 10-CHO-THF (19%) (Horne et al., 
1989).  
1.1.1.2 Folate transport 
The transport of folate into cells is carried out by three main classes of 
transporters: the reduced folate carrier (RFC), folate receptor proteins (Folr), and the 
proton coupled folate transporter (PCFT). RFC is the major folate transporter that 
delivers folates to most tissues and is ubiquitously expressed in mice and humans (Liu et 
al., 2005; Whetstine et al., 2002). RFC has a very low affinity for folic acid, transporting 
only reduced folates, and its activity is highly pH dependent (Huang et al., 1997). RFC is 
maximally active at pH 7.4, and its activity drops off sharply as pH decreases (Zhao et 
al., 2004). Transport of folates by RFC proceeds by a bidirectional anion antiport 
mechanism (Goldman, 1971; Henderson and Zevely, 1983; Yang et al., 1984). 
Nullizygous deletion of RFC is embryonic lethal in mice. Folate supplementation will 
allow survival of embryos until birth, but pups do not survive for more than two weeks 
(Zhao et al., 2001). 
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The folate receptor protein (also known as folate binding protein, Folbp) class of 
transporters are glycolipid linked proteins on the extracellular side of the plasma 
membrane that import folate unidirectionally into the cell by an endocytotic process 
(Sabharanjak and Mayor, 2004). There are three homologues of Folr expressed in 
mammalian cells. Folr1 is expressed both during development and in adults (Elwood, 
1989; Kennedy et al., 2003). Folr2 is expressed only in cancer cells and during 
development, primarily in the placenta (Ross et al., 1999). Folr3 is expressed only in 
hematopoetic cells (Shen et al., 1994). While deletion of Folr2 has no phenotype 
(Piedrahita et al., 1999), Folr1 is required for embryonic development. Mice lacking 
Folr1 do not survive past embryonic day (E) 10 (Piedrahita et al., 1999). Maternal folate 
supplementation with low doses of folate allows the embryos to survive longer with a 
variety of defects. Higher doses of folate allow some embryos to survive until birth, but 
survivors have consistently low serum folate (Spiegelstein et al., 2004).  
Mouse PCFT is highly expressed in the duodenum and proximal jejunum (Qiu et 
al., 2007) and is the primary transporter involved in intestinal absorption of dietary 
folates (reviewed in (Zhao et al., 2011)). PCFT is a proton coupled symporter and is most 
active at low pH (Chattopadhyay et al., 2007; Qiu et al., 2006). PCFT can transport a 
variety of folate species, having the highest affinity for folic acid, 5-CH3-THF, and 5-
CHO-THF. Defects in PCFT are associated with hereditary folate malabsorption (Qiu et 
al., 2006). Although deletion of PCFT in mice is not lethal, mice lacking PCFT show 
systemic folate deficiency that is characterized by accumulation of immature 
erythroblasts in the bone marrow and spleen, increased apoptosis in intermediate 
erythroblasts, and decreased release of reticulocytes from the bone marrow and spleen 
(Salojin et al., 2011).  
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Transport of folates into the mitochondria from the cytoplasm is accomplished by 
the mitochondrial folate transporter (MFT). MFT was first identified in the glyB line of 
CHO cells, which is auxotrophic for glycine and has no measurable mitochondrial folates 
(Titus and Moran, 2000). When glyB CHO cells were transfected with the wild-type 
hamster MFT cDNA the glycine auxotrophy was rescued and the cells were able to 
accumulate mitochondrial folates (McCarthy et al., 2004). Although the exact form of 
folate imported by MFT in vivo is currently unknown, isolated mitochondria from rat 
liver appear to preferentially uptake the reduced folates 5-CH3-THF and 5-CHO-THF and 
have low affinity for folic acid (Horne et al., 1992). Between 5-CH3-THF and 5-CHO-
THF, 5-CHO-THF is more likely to be the physiologically relevant substrate. The only 
known enzyme to utilize 5-CH3-THF is methionine synthase, but it has only been found 
to localize to the cytoplasm (Rassin and Gaull, 1975). On the other hand, CH
+
-THF 
synthetase can catalyze the conversion of 5-CHO-THF to CH
+
-THF and has been 
reported to localize to the mitochondria (Bertrand et al., 1995; Huang and Schirch, 1995).  
1.1.2 Compartmentalization of One-Carbon Metabolism 
1.1.2.1 Overview of Folate-dependent One-Carbon Cycle 
In Eukaryotes, folate-dependent one-carbon (1C) metabolism is a highly 
compartmentalized process in which mitochondria play a central role (reviewed in 
(Tibbetts and Appling, 2010)). There is an exchange of 1C units across the mitochondrial 
membrane that generally proceeds in a clockwise direction as seen in Figure 1.2, with 1C 
donors such as serine and glycine being oxidized to formate in the mitochondria which is 
then released into the cytoplasm. The core of the pathway in both compartments is 
catalyzed by the methylene-tetrahydrofolate (MTHFD) gene family (reactions 1-3 and 
1m-3m). A single trifunctional enzyme, MTHFD1, is responsible for the cytoplasmic 
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Figure 1.2 Compartmentalization of folate-dependent 1C metabolism. End products of 
1C metabolism are in red. 1C donors are in blue. Activated 1C units carried 
by THF are in green. Reactions are catalyzed by the following: 1, 2, and 3, 
MTHFD1; 1m, MTHFD1L; 2m and 3m, MTHFD2 or MTHFD2L; 4, 4n, 
and 4m, SHMT; 5, GCS; 6, CH2-THF reductase; 7, methionine synthase; 8, 
dimethylglycine (DMG) dehydrogenase; 9, sarcosine dehydrogenase; 10 and 
10n, thymidylate synthase; 11, 10-CHO-THF dehydrogenase (only the 
mitochondrial activity of this enzyme is shown, but it has been reported in 
both compartments in mammals); 12, methionyl-tRNA formyltransferase; 
13, dihydrofolate (DHF) reductase; 14, betaine-homocysteine 
methyltransferase. SAH, S-adenosylhomocysteine; SAM, S-
adenosylmethionine; Hcy, homocysteine. Figure adapted from (Tibbetts and 
Appling, 2010).  
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10-formyl-tetrahydrofolate (10-CHO-THF) synthetase, 5,10-methenyl-THF (CH
+
-THF) 
cyclohydrolase, and 5,10-methylene (CH2-THF) dehydrogenase activities (reactions 1-3). 
Mitochondrially derived formate in the cytoplasm can be attached to THF by the 
synthetase activity of the MTHFD1. The 10-CHO-THF that is formed can either be used 
for de novo purine synthesis or reduced to CH2-THF via the cyclohydrolase and 
dehydrogenase activities of MTHFD1. This CH2-THF is available for thymidylate 
synthesis (reaction 10) or can be further reduced to 5-methyl-THF for use in the methyl 
cycle (reactions 6 and 7). 
The mitochondrial 1C pathway begins with the formation of 5,10-methylene-
tetrahydrofolate (CH2-THF). While serine is the primary 1C donor (reaction 4m) (Davis 
et al., 2004; Pike et al., 2010), glycine (reaction 5), dimethyglycine (reaction 8), and 
sarcosine (reaction 9) can also serve as 1C donors for the formation of CH2-THF. 
Mitochondrial CH2-THF dehydrogenase and CH
+
-THF cyclohydrolase activities are 
catalyzed by the bifunctional enzymes MTHFD2 and MTHFD2L (reactions 3m and 2m). 
The final step, the formation of formate from 10-CHO-THF, is catalyzed by the 
monofunctional enzyme MTHFD1L (reaction 1m).  
The four members of the MTHFD gene family share a similar sequence and 
domain structure. Both MTHFD1 and MTHFD1L have two structural domains: a large 
CHO-synthetase domain and a smaller CH2-THF dehydrogenase/ CH
+
-THF 
cyclohydrolase domain. While both domains of MTHFD1 are catalytically active, only 
the synthetase domain of MTHFD1L is active (Christensen and Mackenzie, 2008; 
Walkup and Appling, 2005). MTHFD2 and MTHFD2L both lack the synthetase domain 
and are composed only of the smaller dehydrogenase/cyclohydrolase domain (Bolusani et 
al., 2011; Mejia et al., 1986). Unlike MTHFD1, the mitochondrial proteins MTHFD1L, 
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MTHFD2, and MTHFD2L contain an N-terminal mitochondrial targeting sequence 
(Bolusani et al., 2011; Mejia and MacKenzie, 1988; Prasannan et al., 2003). 
1.1.2.2 Mitochondrial One-Carbon Metabolism 
The 1C pathway in the mitochondria begins with the formation of CH2-THF from 
one of several 1C donors including serine, glycine, dimethylgycine, and sarcosine. Serine 
is the major 1C donor in mammals (Davis et al., 2004; Pike et al., 2010). The formation 
of CH2-THF from serine is catalyzed by the mitochondrial serine 
hydroxymethyltransferase (SHMT2, reaction 4m in Figure 1.2). In this reaction, the 3-
carbon of serine is transferred to THF, making CH2-THF and also forming glycine. 
SHMT2 is ubiquitously expressed, being found in most adult tissues as well as embryos 
(Fujioka, 1969; Motokawa and Kikuchi, 1971; Thompson et al., 2001). 
The oxidation and cleavage of glycine to form CH2-THF is catalyzed by the 
glycine cleavage system (GCS, reaction 5 in Figure 1.2). The oxidative cleavage of 
glycine results in the formation of CO2, NH4, CH2-THF, and NADH. GCS is a protein 
complex composed of four different subunits: glycine decarboxylase (GLDC or P-
protein), aminomethyltransferase (AMT or T-protein), dihydrolipoyl dehydrogenase 
(GCSL or L-protein), and a hydrogen transfer protein known as the H-protein (GCSH) 
(Kikuchi, 1973). GCS is essential both in adults and during embryogenesis. Disruption of 
GCS causes the accumulation of glycine and can lead to a condition known as nonketotic 
hyperglycinemia (NKH), which can cause severe neurological symptoms (Hamosh and 
Johnston, 2001). In mice, deletion of either AMT or GLDC results in NKH-like 
symptoms and leads to neural tube defects (NTDs) (Narisawa et al., 2012; Pai et al., 
2015). 
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Dimethylglycine and sarcosine, both intermediates in the oxidation of choline, can 
also serve as 1C donors in the mitochondria. The enzymes dimethylglycine 
dehydrogenase and sarcosine dehydrogenase catalyze the oxidative demethylation of 
dimethylglycine and sarcosine respectively, leaving glycine as the final product (Figure 
1.2, reactions 8 and 9). The demethylation catalyzed by either enzyme will result in the 
formation of CH2-THF when THF is present (Porter et al., 1985). In the absence of THF 
both enzymes are still active, but instead release the methyl group as formaldehyde 
(Wittwer and Wagner, 1980). Formaldehyde in the mitochondria can be oxidized to 
formate by a mitochondrial aldehyde dehydrogenase (ALDH2) and may provide a source 
of mitochondrial formate, particularly during folate deficiency (Dorokhov et al., 2015; 
Morrow et al., 2015).  
Once CH2-THF is formed, it can then be oxidized in two consecutive steps to 10-
CHO-THF. Two mitochondrial bifunctional enzymes, MTHFD2 and MTHFD2L, carry 
both the CH2-THF dehydrogenase (Figure 1.2, reaction 3m) and CH+-THF 
cyclohydrolase (Figure 1.2, reaction 2m) activities necessary to facilitate this conversion. 
It is currently unknown why mitochondria possess these redundant enzymatic activities. 
Of the two isozymes, less work has been done to characterize MTHFD2L. Our lab has 
shown that MTHFD2L is expressed in both embryonic and adult tissues, but the exact 
timing of its expression during development and tissue distribution in adults had not been 
fully elucidated prior to the work that will be described in Chapter 2 (Bolusani et al., 
2011). MTHFD2L is NAD
+
-dependent at saturating substrate concentrations, but work 




 with almost equal 
affinity at physiological substrate concentrations (Shin et al., 2014).  
Unlike MTHFD2L, MTHFD2 expression is almost entirely restricted to 
transformed cells and developing tissue (Di Pietro et al., 2004; Mejia and MacKenzie, 
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1985, 1988). MTHFD2 is essential for development in mice. By E12.5 embryos lacking 
MTHFD2 are smaller and more pale than their wild-type littermates, and live MTHFD2-
null embryos are not observed past E15.5. Embryonic lethality appears to be caused by a 
defect in hematopoiesis (Di Pietro et al., 2002). Though the CH2-THF dehydrogenase 
activity of MTHFD2 has been reported to be strictly NAD
+
-dependent, these experiments 
were not carried out at physiological substrate concentrations (Mejia and MacKenzie, 





 in the oxidation of CH2-THF at physiologically relevant substrate 
concentrations (Minhye Shin, personal communication). More work will be needed to 
identify differences in MTHFD2 and MTHFD2L that could explain the existence of two 
dehydrogenase/cyclohydrolase enzymes in the mitochondria. 
 Several potential fates await 10-CHO-THF formed in the mitochondria. It can be 
used for formylation of the initiator tRNA for synthesis of mitochondrial proteins (Figure 
1.2, reaction 12), oxidized to CO2 (Figure 1.2, reaction 11), or released as formate (Figure 
1.2, reaction 1m). Like in bacteria, initiation of protein synthesis typically requires a 
formylated initiator tRNA (fMet-tRNA
Met
) (Kozak, 1983). In mammals this reaction is 
catalyzed by mitochondrial methionyl-tRNA formyltransferase (MTFMT). Although 
there is some indication from work with yeast that fMet-tRNA
Met 
is not absolutely 
required for initiation of translation (Li et al., 2000), mutations have been identified in the 
human MTFMT that lead to defects in mitochondrial protein synthesis (Tucker et al., 
2011). 
Another possibility is that 10-CHO-THF can be oxidized to CO2 and THF in an 
NADP
+
 dependent reaction by the mitochondrial 10-CHO-THF dehydrogenase (formerly 
called FTD, encoded by the Aldh1l2 gene). ALDH1L2 activity has been detected in the 
mitochondria of rat liver, retina, and brain (Barlowe and Appling, 1988; Neymeyer and 
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Tephly, 1994). Recent work has highlighted the importance of 1C metabolism in 
contributing to NADPH production in cancer cells (Ducker et al., 2016; Tedeschi et al., 
2013). The total flux of 1C units generated from serine exceeds the synthetic 
requirements of cancer cells, so the oxidation of some of these 1C units to CO2 and 
simultaneous production of NADPH by ALDH1L2 likely plays an important role in 
cancer cell proliferation (Tedeschi et al., 2013). 
Finally, 10-CHO-THF can be oxidized to formate by the synthetase activity of 
MTHFD1L. In this reaction, ATP is produced from ADP and Pi and the formyl group is 
released as formate. Once produced, formate rapidly effluxes from the mitochondria into 
the cytoplasm (Barlowe and Appling, 1988; García-Martínez and Appling, 1993). 
MTHFD1L has been found to be expressed in both embryos and adult tissues (Pike et al., 
2010; Prasannan et al., 2003). MTHFD1L is essential for embryonic development in mice 
(Momb et al., 2013), and mutations have been found in the human gene that are 
associated with an increased risk of NTDs (Minguzzi et al., 2014; Parle-McDermott et 
al., 2009). MTHFD1L expression may also be important in some types of cancer; 
MTHFD1L expression has been found to be upregulated in breast cancer cells (Selcuklu 
et al., 2012). 
1.1.2.3 Cytoplasmic One-Carbon Metabolism 
Formate released from the mitochondria into the cytoplasm can be reattached to 
THF by the synthetase activity of the cytoplasmic trifunctional MTHFD1 (Figure 1.2, 
reaction 1). This synthetase reaction forms 10-CHO-THF and consumes one ATP, 
meaning that there is no net synthesis of ATP from the mitochondrial 10-CHO-THF 
synthetase reaction. This 10-CHO-THF can again proceed in one of several directions. 
10-CHO-THF can be oxidized to CO2 and THF by the cytoplasmic 10-CHO-THF 
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dehydrogenase ALDH1L1. ALDH1L1 is highly expressed in adult livers, accounting for 
approximately 1.2% of the total cellular protein (Cook and Wagner, 1982). Unlike its 
mitochondrial homologue, ALDH1L1 is downregulated in most cancer cells (Krupenko, 
2009; Krupenko and Oleinik, 2002). 
One of the major roles of 10-CHO-CHF in the cytoplasm is as a substrate for de 
novo purine synthesis (Figure 1.2). Two reactions during de novo purine synthesis 
incorporate the formyl group from 10-CHO-THF into the growing purine ring. The 
reactions catalyzed by GAR transformylase and AICAR transformylase incorporate the 
formyl group into carbons 8 and 2 respectively of the purine ring (Barlowe and Appling, 
1988; Pasternack et al., 1994; Tibbetts and Appling, 1997, 2000). 
10-CHO-THF can also be reduced to CH2-THF by the dehydrogenase and 
cyclohydrolase activities of MTHFD1, reversing the oxidation that was done in the 
mitochondria. This cytoplasmic CH2-THF can be used as a substrate for thymidylate 
synthesis (Figure 1.2, reaction 10). Thymidylate synthase catalyzes the reductive 
methylation of dUMP forming dTMP and oxidizing THF to dihydrofolate (Hardy et al., 
1987). THF can be reformed from dihydrofolate by DHFR. As growing cancer cells 
require dTMP synthesis to support proliferation, thymidylate synthase is a common target 
for chemotherapeutic agents (Hardy et al., 1987; Peters et al., 2002). 
Finally, CH2-THF can be irreversibly reduced to CH3-THF by 
methylenetetrahydrofolate reductase (MTHFR) for use in the methylation cycle (Figure 
1.2, reaction 6). Sufficient supply of 1C units to the methyl cycle is critical for proper 
cellular function, and disruption of MTHFR has been implicated in a variety of disorders 
including cardiovascular disease, neural tube defects, Alzheimer's disease, and autism 
(Liew and Gupta, 2015; Rai, 2016a, 2016b; Román, 2015; Sener et al., 2014; Yang et al., 
2015). Increased risk for many of these disorders is associated with a common 
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polymorphism in MTHFR (C677T) which reduces the activity of MTHFR (Frosst et al., 
1995). The frequency of the T allele is variable but can reach as high as 40% in some 
populations (Alluri et al., 2005; Li et al., 2005; Wang et al., 2005). Methionine synthase 
catalyzes the entry of the 1C unit from CH3-THF into the methyl cycle by methylating 
homocysteine to form methionine in a vitamin B12-dependent reaction (Figure 1.2, 
reaction 7). Methionine is adenylated by S-adenosylmethionine synthetase to make the 
universal methyl donor S-adenosylmethionine (SAM) (Cantoni, 1951). SAM is involved 
in the methylation of a variety of biomolecules including proteins, DNA, RNA, and 
phospholipids (reviewed in (Chiang et al., 1996; Su et al., 2016)). S-
adenosylhomocysteine (SAH) is released as a byproduct of the methylation reaction and 
broken down into homocysteine and adenosine by SAH hydrolase (Turner et al., 2000). 
This homocysteine can either be remethylated back to methionine or enter the 
transsulfuration pathway to synthesize cysteine (Mudd et al., 1965). 
1.1.2.4 Nuclear One-Carbon Metabolism 
Recent studies have shown that folate dependent synthesis of dTMP can also take 
place in the nucleus. During S-phase, several folate-dependent enzymes localize to the 
nucleus. Thymidylate synthase, DHFR, and SHMT1 all undergo sumoylation and 
localize to the nucleus (Anderson et al., 2007; Woeller et al., 2007). In addition, there is a 
splice variant of SHMT2 lacking exon 1 (SHTM2α) that has also been shown to localize 
to the nucleus (Anderson and Stover, 2009). Finally, MTHFD1 also localizes to the 
nucleus during S-phase (Field et al., 2014). Although MTHFD1 is not strictly required for 
dTMP synthesis, its transport to the nucleus could provide "on-site" production of CH2-
THF to enhance dTMP synthesis. This localization of a dTMP synthetic system to the 
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nucleus appears to be critical during S-phase as disruption of this system in the nucleus 
leads to increased accumulation of uracil in DNA (MacFarlane et al., 2011). 
1.2 FOLATE METABOLISM IN EMBRYOGENESIS AND NEURULATION 
1.2.1 Mammalian Neural Tube Closure 
Embryogenesis is a highly complex process requiring the coordination of cell 
division, differentiation, and migration to form an organism composed of specialized 
organs and tissues from a single cell. One of the most important events during 
embryogenesis is neurulation. During neurulation, a region of surface ectoderm on the 
dorsal side of the embryo called the neural plate folds and fuses in order to form a hollow 
tube known as the neural tube. The neural tube is the precursor to the brain and spinal 
cord, which make up the central nervous system. Proper closure of the neural tube is 
critical for the development of a healthy and functional organism, and a variety of factors 
including genetics, maternal diet, and environment can adversely affect it.  
Neurulation first begins around 18 days post conception in humans (day 8 in 
mice) with the thickening of the dorsal midline ectoderm to form the neural plate 
(reviewed in (Copp et al., 2003; Detrait et al., 2005). The neural plate first forms near the 
cranial region of the embryo and extends both towards the anterior (rostral) and posterior 
(caudal) ends of the embryo through a process known as convergent extension. During 
convergent extension, cells migrate medially and intercalate along the dorsal midline to 
both narrow and extend the neural plate. The two lateral edges of the neural plate (neural 
folds) begin to extend and then bend about a central axis known as the median hinge 
point (MHP). The extended neural folds then bend again about halfway from the MHP at 
the dorsolateral hinge points. This brings the ends of the neural folds together and allows 
them to fuse, forming the neural tube. In mice, fusion of the neural folds is initiated at a 
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minimum of three different sites along the length of the embryo, but there is likely only 
one initiation site in humans. In either species however, fusion of the neural folds extends 
both rostrally and caudally from the point of initiation. The neural tube is generally fully 
formed by day 28 in humans (day 10.5 in mice). When the neural folds fail to fuse 
correctly, it can lead to one of several types of NTDs depending on where the failure 
occurred. Failure of the neural tube to close in the mid/hindbrain region is called 
exencephaly and leaves brain tissue exposed outside of the skull. Exencephaly can 
develop into the more severe anencephaly where the brain tissue has degraded. If fusion 
on the spine fails to initiate, the neural tube remains open along the length of the spine 
and is called craniorachischisis. Spina bifida occurs when fusion is initiated on the spine, 
but caudal fusion fails before the tube can be fully closed.  
Happening concurrently with neural tube closure is another important process 
known as neural crest cell (NCC) migration (reviewed in (Huang and Saint-Jeannet, 
2004)). NCCs are transient cells that form below the ectoderm in proximity to the neural 
tube around the time of closure. Upon induction by a variety of signals originating from 
both the ectoderm and the mesoderm, NCCs will delaminate and migrate throughout the 
embryo, forming numerous tissues and structures. NCCs forming at different regions 
along the spine will give rise to different sets of derivatives. NCCs at the anterior of the 
neural tube form cranial crest cells. These will eventually form craniofacial bone and 
cartilage, connective tissue, and neurons in the face. Just posterior to the cranial crest 
cells are the vagal crest cells. These give rise to pigment cells, enteric neurons, and 
smooth muscle in the cardiovascular system. Trunk NCCs form pigment cells, much of 
the neurons that comprise the peripheral nervous system, and the adrenal medula. At the 
posterior of the neural tube, sacral NCCs form neurons of the lower intestines. 
 16 
Disruptions to either formation, induction, or migration of NCCs are responsible for a 
range of birth defects including craniofacial, cardiovascular, and pigmentation defects.  
1.2.2 History of Folic Acid Fortification in the United States 
 The link between low folate status in pregnant women and risk of NTDs first 
became apparent in the 1960s and 1970s (Hibbard, 1964, 1967; Smithells et al., 1976). 
Nearly two decades later, two randomized, controlled trials established that 
periconceptional folic acid supplementation could be preventative of NTDs. The first 
involved women who were at high risk of having an NTD affected pregnancy, due to a 
history of a previously affected pregnancy. It was found that folic acid supplementation 
reduced the risk of NTD reoccurrence by approximately 70% (MRC Vitamin Study 
Research Group, 1991). The following year, another study demonstrated that the first 
occurrence of NTDs could also be prevented by periconceptional supplementation of 
folic acid (Czeizel and Dudás, 1992). Consequently, the CDC recommended that all 
women who were capable of becoming pregnant consume 400 μg/day folic acid in an 
effort to prevent NTDs (Centers for Disease Control, 1992). Unfortunately, the success of 
the recommendation alone was limited; a survey found that as few as 29% of women 
consumed the recommended amount of folic acid by 1998 (Centers for Disease Control, 
1999). In addition, up to 50% of pregnancies in the United States are unplanned, and 
many women may not discover they are pregnant until after the point of neural tube 
closure (Finer and Henshaw, 2006). In 1996, to try to ensure that all women of 
childbearing age received sufficient levels of folate in their diet, the US Food and Drug 
Administration mandated that all enriched cereal-grains be fortified with 140 μg folic 
acid /100 g (Food and Drug Administration, 1996). Several studies have evaluated the 
effectiveness of fortification on decreasing NTDs in the US and have found that NTDs 
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decreased by amounts ranging from 19-31% (Boulet et al., 2008; Honein et al., 2001; 
Williams et al., 2002). Despite this success, some cases of NTDs appear to be resistant to 
folate supplementation (as seen by the 30% reoccurrence rate in the MRC study). More 
work is needed to understand the mechanism of the protective effect of folate 
supplementation and why some NTDs cannot be rescued by folate supplementation.  
1.2.3 Mouse Models of Folate Metabolism and Neural Tube Defects 
One of the most common tools used to study mammalian neural tube closure is 
mouse mutants or strains that develop NTDs. As of 2010, over 240 such strains have 
been reported (Harris and Juriloff, 2010). Few of these mutants have been tested for 
responsiveness to folic acid and even fewer target genes directly involved in folate 
metabolism. Genes related to folate metabolism that have been targeted include Folr1, 
Shmt1, Amt, Gldc, and Mthfd1l. Only Folr1 and Shmt1 were found to be responsive to 
folate supplementation. Both these and the folate unresponsive genes will be discussed in 
more detail below.  
1.2.3.1 NTD Mutants Responsive to Folate 
Mouse embryos containing a homozygous deletion of either Folr1 or Shmt1 have 
both been shown to exhibit neural tube defects that are sensitive to folate status. Deletion 
of Folr1 essentially renders embryos folate deficient by severely disrupting cellular 
uptake of folate. Homozygous deletion of Folr1 is embryonic lethal, and Folr1
-/-
 embryos 
do not survive past E10. Folr1
-/- 
embryos are developmentally delayed and die before the 
point of neural tube closure (Piedrahita et al., 1999). Supplementation of dams with low 
doses of folate, in the form of either 5-CH3-THF or 5-CHO-THF, improved survivability 
of Folr1
-/-
 embryos, albeit with a plethora of developmental defects. Observed defects 
include NTDs (exencephaly, encephalocele, and craniorachischisis), craniofacial, 
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abdominal, and ocular defects. Larger doses of folate conferred a higher level of 
protection against these defects and allowed some Folr1
-/- 
mice to survive until 
adulthood. Surviving Folr1
-/- 
mice were found to have defects including brachycephaly, 
ocular defects, and teeth malocclusions. Folr1
-/-
 mice also had much lower serum folate 
than their littermates (Spiegelstein et al., 2004).  
When dams are fed a folate replete diet, Shmt1
-/-
 mice appear to develop normally, 
suggesting that cytosolic SHMT activity is not essential for development under normal 





 embryos have NTDs at a higher rate than Shmt
+/+
 littermates, 
though the rate is highest in Shmt1
-/-
 embryos (14%) (Beaudin et al., 2011). The 
predominant NTD found in these mice is exencephaly. Due to the involvement of 
SHMT1 in thymidylate synthesis in the nucleus, the authors suggest that disruption of 
thymidylate synthesis may be one of the main factors leading to NTDs in these mice 
(Anderson and Stover, 2009).  
1.2.3.2 NTD Mutants not Responsive to Folate 
Perhaps more interesting than the folate responsive mouse models are the folate 
metabolism-related mutants that do not respond to folic acid supplementation. These 
mutants can give us a better understanding of NTDs in humans that are resistant to folate 
supplementation and may lead to alternate supplements or therapies that can further 
reduce the rate of NTDs in humans.  
Our lab has recently reported the characterization of a homozygous deletion of 
Mthfd1l in mice. We found that Mthfd1l null (Mthfd1l
z/z
) mice did not survive past E12.5 
and had aberrant neural tube closure characterized by exencephaly, craniorachischisis, or 
wavy neural tubes (Momb et al., 2013). Supplementation of dams with 5-CHO-THF did 
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not rescue the NTD phenotype (Jessica Momb, unpublished data). However, maternal 
supplementation with formate, the end product of mitochondrial folate metabolism 
produced by MTHFD1L, not only increased the survival of embryos past E12.5, but also 
reduced the incidence of NTDs. Another folate resistant NTD mouse is the curly tail 
mouse (Seller, 1994). Curly tail mice are characterized by a hypomorphic allele of the 
grainyhead-like 3 (Grhl3) transcription factor. Increasing expression of Grhl3 reduces 
spina bifida in the curly tail mouse but is not protective against exencephaly (Gustavsson 
et al., 2007). It has recently been shown that curly tail mice also express abnormally low 
levels of Mthfd1l, suggesting the possibility that it is the decreased MTHFD1L activity 
that is responsible for exencephaly in these mice. In support of this idea, it was found that 
maternal formate supplementation reduced the rates of both spina bifida and exencephaly 
in curly tail mice (Sudiwala et al., 2016). 
Two other genes involved in mitochondrial folate metabolism have been found to 
be associated with NTDs. Deletion of either Gldc or Amt, both of which are found in the 
mitochondrial GCS, causes NTDs in embryos (Narisawa et al., 2012; Pai et al., 2015). 
The primary defect observed was exencephaly, but a smaller percentage of mice 
developed craniorachischisis. Folic acid supplementation in either mouse line was 
ineffective in rescuing the NTD phenotype. As with Mthfd1l
-/-
 mice, maternal formate 
supplementation decreased NTDs in Gldc
-/-
 mice (Pai et al., 2015). Amt
-/-
 mice were not 
tested with formate, but another 1C metabolite, methionine, was shown to decrease NTDs 
(Narisawa et al., 2012).  
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Chapter 2: Characterization of expression of MTHFD gene family and 
alternative splicing of MTHFD2L 
2.1 INTRODUCTION 
For decades the only known mitochondrial CH2-THF dehydrogenase/CH
+
-THF 
cyclohydrolase was MTHFD2 (Mejia and MacKenzie, 1985; Mejia et al., 1986). This 
protein could only be detected in immortalized mammalian cells, embryos, or 
nondifferentiated tissues, but not in adult differentiated tissues (Christensen and 
Mackenzie, 2008). Although it had been shown that intact adult liver mitochondria were 
capable of oxidizing the 3-carbon of serine to formate and CO2 in a THF dependent 
manner, the enzyme responsible for this activity remained unidentified (Barlowe and 
Appling, 1988).  
In 2011 our lab reported the discovery of a new CH2-THF dehydrogenase, 
MTHFD2L (Bolusani et al., 2011). MTHFD2L is homologous to MTHFD2, sharing 60-
70% sequence identity. Using a V5 epitope-tagged rat MTHFD2L expressed in CHO 
cells it was shown that MTHFD2L is a mitochondrial protein that is localized to the 
matrix side of the inner mitochondrial membrane. Rat MTHFD2L expressed in yeast was 
shown to possess NADP
+
-dependent CH2-THF dehydrogenase activity. The study 
identified alternative splicing of two different exons, exon 2 and exon 8, in MTHFD2L in 
both humans and rats. Details of alternative splicing of these exons will be discussed in 
more detail below. 
It is currently unknown why mammals might possess two mitochondrial CH2-
THF dehydrogenases. One possibility is that the two proteins differ enzymatically, either 
in activity or cofactor specificity. Another possibility is that they differ in their tissue 
distribution or expression profiles. 
 21 
We have reported the enzymatic characterization of purified rat MTHFD2L (Shin 
et al., 2014). MTHFD2L possesses both CH2-THF dehydrogenase and CH
+
-THF 





 as a cofactor, but activity with NAD
+
 also requires the presence of 
magnesium and inorganic phosphate. At saturating substrate concentrations, MTHFD2L 
shows a preference for NAD
+





 at physiological substrate concentrations (Shin et al., 2014).  
This chapter will describe my work on the characterization of the expression 
profile of MTHFD2L in developing mouse embryos and adult mice. It will also describe 
my investigation of the expression, enzymatic activity, and subcellular localization of 
MTHFD2L splice variants. 
 
Portions of this work have been previously published. (Shin, M, Bryant, JD, 
Momb, J, Appling, DR (2014) J. Biol. Chem. 289(22): 15507-15517). These sections will 
be indicated by quotation marks and additional indentation. 
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2.2 METHODS AND MATERIALS 
2.2.1 Materials 





 were purchased from U. S. Biological (Swampscott, MA) and Sigma, 
respectively. HRP-conjugated goat anti-rabbit IgG was from Invitrogen, and the 
ECL Plus chemiluminescence detection kit was from GE Healthcare Life 
Sciences. THF was prepared by the hydrogenation of folic acid (Sigma) using 
platinum oxide as a catalyst and purification of the THF product on a DEAE 
cellulose column (Sigma)(Blakley, 1957; Curthoys and Rabinowitz, 1971). CH2-
THF was prepared nonenzymatically from THF and formaldehyde 
(Fisher)(Appling and West, 1997). The yield of CH2-THF was determined by 
solving the equilibria of THF, formaldehyde, and β-mercaptoethanol (Kallen and 
Jencks, 1966)." 
2.2.2 Mouse Work 
"All animals used within this study were maintained according to 
protocols approved by the Institutional Animal Care and Use Committee of The 
University of Texas at Austin and conform to the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals." 
2.2.3 RNA Isolation and cDNA Synthesis 
"Tissue was collected from six male and six female C57BL/6 mice 
between 4 and 6 weeks of age. Embryos were dissected at the days indicated. For 
embryonic days 8.5–11.5, five embryos were pooled for each time point; for 
embryonic days 12.5–17.5, three embryos were pooled for each time point. Tissue 
and embryos were washed with PBS and then stored in RNAlater (Applied 
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Biosystems Inc. (ABI)). Embryos from each day were pooled prior to RNA 
isolation. RNA was isolated using TRI reagent (ABI) and treated with 
TurboDnase (Invitrogen) following the manufacturer's instructions. RNA quality 
was verified by confirmation of the presence of 28S and 18S rRNA bands on an 
agarose gel. cDNA was synthesized using SuperScript III (Invitrogen) and 
random hexamers." 
2.2.4 Real Time PCR 
"Primers against mouse MTHFD1, MTHFD1L, MTHFD2, MTHFD2L, 
eEF2 (eukaryotic translation elongation factor 2), and TBP (TATA-box-binding 
protein) were designed using Primer-BLAST (Ye et al., 2012) to yield an 
amplicon between 95 and 125 base pairs long and cross at least one exon-exon 
junction (see Table 2.1). Primers were checked individually against plasmids 
containing mouse MTHFD1, MTHFD1L, MTHFD2, and MTHFD2L to ensure 
that the primer pairs were specific to the target gene. Quantitative real-time PCR 
was performed using SYBR Green (Qiagen) on an ABI ViiA 7 using a two-step 
program (50 °C for 2 min and then 95 °C for 10 min followed by 40 cycles of 95 
°C for 15 s and 60 °C for 15 s). The specificity of the reaction was verified by 
melt curve analysis. Relative expression values from embryos were calculated by 
normalizing to TBP (Willems et al., 2006), and values from adult tissues were 
normalized to eEF2 (Kouadjo et al., 2007).  
"We have shown previously that MTHFD2L is alternatively spliced at 
exons 2 and 8 (Bolusani et al., 2011). To determine the abundance of the splice 
variants of MTHFD2L containing exon 2 or exon 8, we designed primer pairs that 
would bind in exons 2 and 3 or in exons 7 and 8, so that they would produce only  
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Primer name Sequence Location 
MTHFD1 F 5'-TTCATCCCATGCACACCCAA-3' Exon 6 
MTHFD1 R 5'-ATGCATGGGTGCACCAACTA-3' Exon 7 
MTHFD1L F 5'-GGACCCACTTTTGGAGTGAA-3' Exon 12 
MTHFD1L R 5'-ATGTCCCCAGTCAGGTGAAG-3' Exon 14 
MTHFD2 F 5'-ACAGATGGAGCTCACGAACG-3' Exon 5 
MTHFD2 R 5'-TGCCAGCGGCAGATATTACA-3' Exon 6 
MTHFD2L F1 5'-GGCGGGAAGATCCAAGAACG-3' Exon 6 
MTHFD2L R1 5'-CGCTATCGTCACCGTTGCAT-3' Exon 7 
MTHFD2L F2 5'-GGCCAGCAGAGAGAAGAGACT-3' Exon 2 
MTHFD2L R2 5'-CCATGATTCCACTCCTTGCT-3' Exon 3 
MTHFD2L F3 5'-GAGGTGATGCAACGGTGAC-3' Exon 7 
MTHFD2L R3 5'-GAATACCCGCAGCCACTATG-3' Exon 8 
eEF2 F 5'-CGCATCGTGGAGAACGTCAA-3' Exon 4 
eEF2 R 5'-GCCAGAACCAAAGCCTACGG-3' Exon 5 
TBP F 5'-CATGGACCAGAACAACAGCC-3' Exon 2 
TBP R 5'-TAAGTCCTGTGCCGTAAGGC-3' Exon 3 
 
Table 2.1 Primers used for expression profiling of the MTHFD gene family in 
embryos and adult tissues.  
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a product from splice variants containing exon 2 or exon 8, respectively. The 
expression values for these primer pairs were normalized to the expression levels 
found using primers MTHFD2L F1 and R1, which bind in exons 6 and 7. There is 
no evidence for alternative splicing of these exons, and they are thus assumed to 
represent the total amount of MTHFD2L transcript, including all splice variants." 
2.2.5 In situ hybridization of whole mouse embryos 
"Mouse embryos ranging from E9.5 to 12.5 were hybridized as described 
previously using digoxigenin-labeled UTP RNA probes (Pike et al., 2010). 
Antisense probes were constructed as described previously (Pike et al., 2010) by 
in vitro transcription using T7 RNA polymerase to transcribe from Riken clone 
1110019K23 (Kawai et al., 2001) linearized with BamHI. Sense probes were 
made by linearizing with XhoI and transcribing with T3 RNA polymerase." 
2.2.6 5,10-Methylene-THF Dehydrogenase Assay 
Full length rat MTHFD2L and MTHFD2L lacking exon 8 in the yeast expression 
vector yEP24 (see below) were transformed into S. cerevisiae strain MWY4.4 (ser1 
ura3–52 trp1 his4 leu2 ade3–65 Δmtd1) using a high efficiency lithium acetate 
transformation procedure (Gietz and Woods, 2002; West et al., 1993). The preparation of 
yeast crude lysates was performed as described previously (Bolusani et al., 2011). 5,10 
methylene-THF dehydrogenase activity of yeast crude lysate was measured using an 
endpoint assay as detailed in (Wagner et al., 2005). The final concentration of reagents in 
the reaction buffer was 50 mM HEPES (pH 8.0), 100 mM KCl, 5 mM MgCl2, 0.4 mM 
CH2-THF, 40 mM β-mercaptoethanol, and either NAD
+
 (1 mM) or NADP
+
 (6 mM). 
Reactions using NAD
+
 also contained 25 mM potassium phosphate. Reactions were 
carried out in PCR tubes then were transferred to a 96 well microplate for absorbance 
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measurements. 60 uL of reaction buffer was added to each tube. 20 uL of yeast crude 
lysate (see below) at a concentration of 7.75 mg/mL was added to each tube. 20 uL of 
THF (1 mM) was added to initiate the reactions. The tubes were incubated at 30
o
C for 5 
minutes, then the reactions were quenched by the addition of 200 uL 3% perchloric acid. 
Blank reactions were also set up in which the perchloric acid was added before the yeast 
crude lysate. The PCR tubes were centrifuged to pellet the precipitated proteins, and the 
supernatant was transferred to a microplate and the absorbance at 350 nm, 900 nm, and 
1,000 nm was measured. Near infrared measurements were used for path length 
correction (Palmer and Williams, 1974). 
2.2.7 In Vivo Yeast Complementation Assay 
"Exon 8 was removed from pET22b-rMTHFD2L by overlap extension 
PCR (Ho et al., 1989) using the primers rD2L-x8 5'/HindIII F (5'-
ATCTAAGCTTATGGCGACGCGGGCCCGT-3'), rD2L-x8 5' R (5'-TAACAG 
CTGCAGCCACTATGATAATCT-3'), rD2L-x8 3' F (5'-CTGCAGCTGTTAA 
GAAGAAGGCCAGC-3'), and rD2L-x8 3'/BamHI R (V5) (5'-TGAT GGATCC 
A GTAGGTGATATTCTTGGCAGCCAG-3'). Following PCR, rMTHFD2L-x8 
was subcloned into YEp24ES (Bolusani et al., 2011; Suliman et al., 2005) using 
the HindIII and BamHI restriction sites. Plasmids were transformed into the yeast 
strain MWY4.5 (ser1 ura3–52 trp1 leu2 his4 ade3–30/65 mtd1), and 
transformants were selected for uracil prototrophy. The in vivo complementation 
assay was performed in this yeast strain as described previously (Bolusani et al., 
2011).  
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"Preparation of crude yeast lysates and immunoblotting were carried out 
as described previously (Bolusani et al., 2011). The protein concentration was 
determined by BCA assay (Thermo Fisher Scientific)." 
2.2.8 Submitochondrial localization of MTHFD2L lacking exon 8 
Rat MTHFD2L lacking exon 8 (see above) was subcloned into the pcDNA3.1 
expression vector (Thermo Fisher Scientific) using the BamHI and HindIII restriction 
sites to make the pcDNA3.1/rD2L-x8 construct. The pcDNA3.1 vector contains a CMV 
promoter for expression in mammalian cell lines and introduces a C-terminal V5 epitope 
tag. pcDNA3.1/rD2L-x8 was transiently transfected into the glyB Chinese hamster ovary 
(CHO) cell line. To do this, the CHO cells were plated onto 6 6 well plates (36 wells in 
total) and grown to approximately 60% confluency. 26 μL of pcDNA3.1/rD2L-x8 DNA 
(1.42 μg/μL) was mixed with 714 μL OptiMEM (Thermo Fisher Scientific). In a separate 
tube, 74 μL was mixed with 666 μL OptiMEM. After leaving at room temperature for 5 
minutes these tubes were combined and incubated at room temperature for 30 minutes. 
This mixture was then added to 29.6 mL OptiMEM that had been prewarmed to 37
o
C. 
The media from all wells was aspirated and wells were washed with 2 mL PBS. After the 
PBS was aspirated, 840 μL of the OptiMEM/Lipofectamine/DNA mixture was added to 
35 wells. Only OptiMEM was added to the 36th well to act as a negative control. Cells 
were incubated at 37
o
C, 5% CO2 for two days. The media was aspirated from all wells 
and wells were washed with PBS. Cells from 34 of 36 wells were trypsinized and pooled. 
Mitochondria were isolated from these cells as described previously (Bolusani et al., 
2011). Cells from the remaining two wells (the negative control and one additional well) 
were treated with 200 μL NP-40 lysis buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, pH 
8.0) to create the whole cell lysate. The isolated mitochondria were pelleted by 
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centrifugation at 12,000 x g and resuspended in 100 μL HMS (0.25 M sucrose, 1 mM 
EGTA, 10 mM HEPES, pH 7.4) containing 0.5% Triton X-100 then incubated on ice for 
30 minutes. This solution was centrifuged at 100,000 x g, and the supernatant was 
transferred to a new tube. The pellet was resuspended in 100 μL HMS (0.5% Triton X-
100) and centrifuged again. The two supernatant fractions were combined to give the 
soluble mitochondrial fraction (MitoS), and the pellet was resuspended in 30 μL HMS 
(0.5% Triton X-100) to give the mitochondrial membrane fraction (MitoP).  
2.3 RESULTS 
2.3.1 Expression of MTHFD Genes During Mouse Embryonic Development 
"It has been reported previously that the MTHFD2 gene is expressed in 
early embryos, but its expression declines as the embryo approaches birth, and the 
MTHFD2 enzyme is found only in nondifferentiated tissues in adults (Di Pietro et 
al., 2004; Pike et al., 2010). We determined the relative expression profiles of all 
four MTHFD gene family members in mouse embryos using real-time PCR, 
normalizing to TBP (TATA-box-binding protein) expression. TBP has been 
determined to be stably expressed at multiple stages of embryonic development, 
making it a suitable housekeeping gene for real-time PCR experiments involving 
embryos (Willems et al., 2006). MTHFD1 and MTHFD1L transcript expression 
was highest at E8.5 and subsequently decreased until expression increased again 
at E13.5–17.5 (Figure 2.1). MTHFD2 expression was low at all embryonic days 
examined. MTHFD2L was also expressed at all embryonic days examined. 
MTHFD2L expression was low at E8.5 but increased beginning at E10.5 (Figure 















































Figure 2.1 Temporal expression profile of MTHFD gene family in mouse embryos. 
The relative expression profiles of MTHFD1 (●), MTHFD1L (■), MTHFD2 
(▲), and MTHFD2L (▼) was determined by real-time PCR as described 
under “Materials and Methods.” The age of the embryos from which the 
RNA was obtained is indicated in embryonic days (birth occurs at E20.0). 
mRNA expression was normalized to that of the TBP transcript. Each point 
represents the mean +/- S.E. of triplicate determinations (error bars are 
included for all data points but are obscured by the data symbol when the 
scatter is small).  
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expression occurs approximately between embryonic days 8.5 and 10.5 during 
mouse embryogenesis.  
"In situ hybridization of whole mouse embryos (Figure 2.2) revealed that 
MTHFD2L is expressed in the neural tube and the forebrain, midbrain, and 
hindbrain, suggesting a possible role in neural tube development. Other areas of 
intense staining included the branchial arches and limb buds, particularly along 
the progress zone." 
2.3.2 Expression of MTHFD Genes in Male and Female Adult Mice 
"Expression of adult MTHFD genes from male and female mice was 
normalized to the expression of eEF2, a housekeeping gene that is stably 
expressed in a wide array of adult tissues (Kouadjo et al., 2007). The MTHFD2L 
transcript was expressed in all of the tissues examined, with the highest 
expression observed in brain and lung and lower expression in liver and kidney 
(Figure 2.3). As has been reported previously, MTHFD1 showed the highest 
expression in liver and kidney (Thigpen et al., 1990). MTHFD1L was most highly 
expressed in brain and spleen. The MTHFD2 transcript could be detected at low 
levels in most tissues, but only testis and spleen expressed it at even a modest 
level. The expression patterns of the four transcripts were similar in males and 
females." 
2.3.3 MTHFD2L Alternative Splicing 
"MTHFD2L transcripts were analyzed by RT-PCR on RNA from human 
brain and placenta as described under 'Materials and Methods.' These analyses 
revealed alternative splicing of two exons in the human MTHFD2L gene. 




Figure 2.2 Spatial distribution of MTHFD2L expression in mouse embryos. "In 
situ hybridizations of whole mount embryos ranging from E9.5 to E12.5 (A–
D) were performed using digoxigenin-labeled UTP RNA probes as 
described under 'Materials and Methods.' C, as shown on the E11.5 
embryo, MTHFD2L is especially prominent in the neural tube (a), forebrain 
(b), midbrain (c), hindbrain (d), branchial arches (e), and somites (f). 
Embryos A–C were imaged at the same magnification (×20). Embryo D was 













Figure 2.3  Tissue specific expression of the MTHFD gene family. The relative 
expression of MTHFD1, MTHFD1L, MTHFD2, and MTHFD2L was 
determined as described under "Materials and Methods." mRNA expression 
was normalized to that of the eEF2 transcript in female (top) and male 



























































































































and placenta RNA (Figure 2.4, B and C). The band intensity of the exon 8 doublet 
was always weak with placenta RNA. Sequence analysis of the cloned PCR 
products confirmed that the larger product of each doublet included the alternate 
exon (2 or 8), and the smaller product of each doublet lacked the alternate exon. 
This alternative splicing thus produces at least three classes of transcripts from the 
human MTHFD2L gene (Figure 2.4, A). In class I transcripts, the 34-bp exon 2 is 
skipped, giving an mRNA that encodes the 347-amino acid protein… In class II 
transcripts, exon 2 is retained; translation of this mRNA from the first AUG 
codon in exon 1 would produce an early termination product of only 60 amino 
acids. However, translation of the class II mRNA from an AUG codon in exon 3 
would give a protein identical to the last 289 amino acids of the class I protein. In 
class III transcripts, both exon 2 and exon 8 are skipped. Based on sequenced RT-
PCR clones and expressed sequence tags in the NCBI EST databases, all three 
transcript classes are expressed in both brain and placenta from adult humans." 
(Bolusani et al., 2011) 
"RT-PCR analysis of RNA isolated from adult rat tissues revealed that 
the MTHFD2L gene is widely expressed (Figure 2.5). The 34-bp exon 2 is also 
found in the mouse and rat MTHFD2L genes. Although the majority of mouse and 
rat expressed sequence tags in the NCBI EST database lack exon 2, there are 
several that contain this exon. RT-PCR on rat brain RNA using primers in exons 1 
and 3 produced two products, although the longer product (containing exon 2) 
was the minor species (data not shown). RT-PCR using primers in exons 7 and 9 
also produced two products with rat RNAs, a 338-bp product containing exon 8 
and a 212-bp product lacking exon 8 (Figure 2.5). Sequence analysis of the 212-
bp product indicated precise splicing of exon 7 to exon 9 with the reading frame 
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intact. In all tissues examined, the exon 8 skipped transcript is the minor species." 
(Bolusani et al., 2011) 
We also examined alternative splicing of MTHFD2L during development. 
"Using total embryo RNA from embryos ages E8.5 to E17.5, we observed that 
exon 2 was present in less than 10% of the transcripts in all of the embryonic days 
examined (Figure 2.5), indicating that the vast majority of MTHFD2L transcripts 
encode a mitochondrial targeting sequence. Exon 8, on the other hand, was found 
to be missing in 20– 45% of the MTHFD2L transcripts throughout embryogenesis 
(Figure 2.5).  
"To determine what effect the removal of exon 8 would have on 
MTHFD2L activity, MTHFD2L lacking exon 8 was expressed in yeast. NAD-
dependent CH2-THF dehydrogenase activity could not be detected in crude yeast 
lysate from yeast cells transformed with the truncated construct (YEp-rD2L-x8; 
Figure 2.6). NAD-dependent CH2-THF dehydrogenase activity was easily 
detectable in lysate from yeast cells transformed with the full-length construct.  
"We next asked whether MTHFD2L lacking exon 8 was active in vivo, 
using a yeast complementation assay (Bolusani et al., 2011). Briefly, this assay 
uses yeast strain MWY4.5, which lacks cytoplasmic CH2- THF dehydrogenase 
activities as well as the 10-formyl-THF synthetase activity of the cytoplasmic 
trifunctional C1-THF synthase (West et al., 1996). Wild-type yeast can produce 
10-CHO-THF for de novo purine biosynthesis from serine using either 
cytoplasmic or mitochondrial 1C pathways (36) (see Figure 1.2). However, 
MWY4.5 is blocked in both pathways to 10-CHO-THF. This blockage creates a 




Figure 2.4  MTHFD2L gene structure and alternative splicing. "A, gene structure, 
alternative splicing, and potential protein products. The entire gene spans 
145 kbp on chromosome 4 at 4q13.3. Exons are shown as numbered black 
bars; introns are shown as thin horizontal lines. Exons are not drawn to 
scale. Three alternative splicing patterns due to skipping of exon 2 and/or 8 
are observed in human brain and placenta….B, RT-PCR analysis of exon 2 
splicing using primers binding in exons 1 and 3... The expected sizes of the 
two products are 335 bp (including exon 2) and 301 bp (excluding exon 2). 
−RT, minus reverse transcriptase control. C, RT-PCR analysis of exon 8 
splicing using primers binding in exons 1 and 9... The expected sizes of the 
two products are 980 bp (including exon 8) and 852 bp (excluding exon 8). 






Figure 2.5 "MTHFD2L expression in adult rat tissues. Total RNA isolated from the 
indicated adult rat tissues was analyzed by RT-PCR as described under 
“Materials and Methods” using primers binding in exons 7 (5'-
CGGTGACCATAGCTCACAGA) and 9 (5'-GCTCTCCCCTGCGATC-
TAGTA). The expected sizes of the two products are 338 bp (including 
exon 8) and 212 bp (excluding exon 8). Lanes 1 and 9 contain DNA size 
markers (sizes indicated on left). Lanes 2–8, reverse transcriptase samples 
(+ RT); lanes 10–16, minus reverse transcriptase controls (− RT); lane 17, 
minus RNA control (− RNA; contained reverse transcriptase). The image is 



















Figure 2.6  Temporal expression profile of MTHFD2L splice variants containing exon 2 
(■) and exon 8 (●) in mouse embryos. MTHFD2L transcripts was 
determined by real-time PCR and analyzed as described under 
“Experimental Procedures.” Each point represents the mean ± S.E. of 
triplicate determinations (‘bars are included for all data points but are 
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Figure 2.7 Dehydrogenase activity of rat MTHFD2L lacking exon 8. S. cerevisiae 
strain MWY4.4 (ser1 ura3–52 trp1 his4 leu2 ade3–65 Δmtd1) was 
transformed to uracil prototrophy with YEp-D2L (wild-type), YEp-D2L-x8 
(lacking exon 8), or empty vector (YEp24). Crude lysates were assayed for 
CH2-THF dehydrogenase activity as described in "Materials and Methods." 
Each bar represents the mean +/- S.D. of duplicate determinations. * 






























Cytoplasmically localized MTHFD2L lacking exon 8 should rescue the adenine 
requirement of MWY4.5 if it is catalytically active in vivo. Transformants of 
MWY4.5 harboring YEp-rD2L-x8, YEp-rD2L (full-length MTHFD2L) (Bolusani 
et al., 2011), or empty vector (YEp24ES) were streaked onto yeast minimal plates 
containing serine as a one-carbon donor or serine adenine and incubated at 30 °C. 
As shown in Figure 2.7, full-length MTHFD2L, expressed from YEp-rD2L as a 
positive control, fully complemented the adenine requirement of MWY4.5, as 
observed previously (Bolusani et al., 2011). However, MTHFD2L lacking exon 8, 
expressed from the rD2L-x8 plasmid, did not complement the adenine 
requirement. An immunoblot of crude yeast lysates from these transformants 
confirmed that the truncated protein was expressed at a level similar to that of the 
full-length protein in control cells (Figure 2.7, inset). These in vitro and in vivo 
results suggest that the MTHFD2L variant lacking exon 8 does not function as a 
CH2-THF dehydrogenase." 
Full-length MTHFD2L (containing exon 8 but lacking exon 2) localizes to the inner 
mitochondrial membrane. We sought to determine if MTHFD2L lacking exon 8 would 
behave similarly in vivo. CHO cells were transiently transfected with rat MTHFD2L 
lacking exon 8 (pcDNA3.1/rD2L-x8) tagged with a V5 epitope. Isolated mitochondria 
were treated with 0.5% Triton X-100 to solubilize the mitochondrial membranes then 
were spun at 100,000 x g in an ultracentrifuge to separate mitochondrial matrix (soluble) 
and membrane (pellet) fractions. The resulting fractions were analyzed by 
immunoblotting with an anti-V5 antibody (Figure 2.8). MTHFD2L lacking exon 8 was 
found predominantly in the mitochondrial pellet fraction indicating it still localizes to the 






Figure 2.8  Expression of MTHFD2L lacking exon 8 in yeast. "S. cerevisiae strain 
MWY4.5 (ser1 ura3 trp1 leu2 his4 ade3–30/65 Δmtd1) was transformed to 
uracil prototrophy with YEp-rD2L (wild type), YEp-rD2L-x8 (lacking exon 
8), or empty vector (YEp24ES). Ura+ transformants were streaked onto 
yeast minimal plates containing serine as a one-carbon donor plus adenine 
(left) or serine alone (right) and incubated at 30 °C for 4 days. Both plates 
also contained leucine, tryptophan, and histidine to support the other 
auxotrophic requirements of MWY4.5. Inset, immunoblot of whole cell 
lysate from MWY4.5 transformed with the indicated plasmids. Each lane 
was loaded with 50 μg of protein. The blot was probed with polyclonal 






















Figure 2.9  Submitochondrial localization of epitope tagged rat MTHFD2L lacking 
exon 8. Protein from the cytoplasmic fraction (Cyt), whole cell lysate of 
untransfected cells (WC-). whole cell lysate of pcDNA3.1/rD2L-x8 
transfected cells (WC+), soluble mitochondrial fraction (MitoS), and 
mitochondrial pellet (MitoP) were subjected to SDS-PAGE and analyzed by 
immunoblotting using anti-V5, anti-porin, and anti-Hsp60. MTHFD2L 
migrated at an apparent molecular mass of 30 KDa, Porin migrated at 30 
KDa, and Hsp60 at 60 KDa. The immunoblot with anti-V5 was overexposed 
(V5 (10 min)) in order to show the expression of the epitope tagged 
MTHFD2L in the WC+ fraction.   
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membrane is unaffected by loss of exon 8. Antibodies against porin (a mitochondrial 
membrane marker) and Hsp60 (a mitochondrial matrix marker) were used to verify the 
integrity of the subfractionation.  
2.4 DISCUSSION 
 
"We determined expression profiles for the entire MTHFD family of genes 
during mouse embryogenesis (Figures 2.2 and 2.3) and in adult tissues (Figure 
2.4). The results for MTHFD1 (cytoplasmic reactions 1–3 (Figure 1.3)) 
and MTHFD1L (mitochondrial reaction 1m) are qualitatively similar to 
previously reported transcript expression patterns in mouse embryos based on a 
staged Northern blot (Pike et al., 2010). Both transcripts are highest in early 
embryos and decrease during embryonic days 9.5–15.5, only to increase again as 
the embryo approaches birth. MTHFD2 and MTHFD2L, on the other hand, 
exhibit very different expression profiles. MTHFD2 expression was low in all 
embryonic days examined, whereas expression of the MTHFD2L transcript 
increased beginning at E10.5 and remained elevated through birth (Figure 2.2). 
These data reveal a switch from MTHFD2 to MTHFD2L expression at about the 
time of neural tube closure in mouse embryos. The spatial expression of 
MTHFD2L is localized to the neural tube, developing brain, branchial arches, and 
limb buds (Figure 2.3). These regions are also areas where MTHFD2 
and MTHFD1L are expressed (Pike et al., 2010), suggesting a role for the 
mitochondrial folate pathway in these embryonic tissues." 
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The widespread expression of MTHFD2L in adult tissues is of particular 
relevance to cancer research. The related mitochondrial isozyme of MTHFD2L, 
MTHFD2, has been identified in a screen of 19 cancer cell types as a protein that is 
highly associated with proliferating cancer cells (Nilsson et al., 2014). Increased 
MTHFD2 expression is associated with increased breast cancer cell migration and 
invasion (Lehtinen et al., 2012) and poor prognosis in patients with breast cancer (Liu et 
al., 2014). MTHFD2 has been suggested as a novel target for anticancer therapy 
(Tedeschi et al., 2015). A BLAST sequence alignment of human MTHFD2L and 
MTHFD2 reveals that the two proteins share 72% sequence identity. While the strong 
association of increased MTHFD2 expression in proliferating cancer cells may make it 
attractive target for anticancer drugs, the high similarity between MTHFD2 and 
MTHFD2L could result in unintended off target effects on MTHFD2L in other tissues. 
Inhibition of MTHFD2L may have negative consequences for the proper function of 
organs such as the brain, heart, and lungs where MTHFD2L is most highly expressed. 
Care would need to be taken when implementing any anticancer drug targeting 
MTHFD2.  
"Why might mammals possess these two distinct mitochondrial 
dehydrogenase/cyclohydrolase isozymes? It appears that under most conditions, 
the majority of 1C units for cytoplasmic processes are derived from mitochondrial 
formate (Tibbetts and Appling, 2010). Oxidation of mitochondrial CH2-THF is 
essential for the production of 10-CHO-THF, which is processed by MTHFD1L 
to provide formate for cytoplasmic export (Figure 1.3). This formate is then 
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reattached to THF for use in de novo purine biosynthesis or further reduced for 
either thymidylate synthesis or remethylation of homocysteine to methionine. 
Modeling studies suggest that the oxidation step (reaction 3m (Figure 1.3)), 
catalyzed by either MTHFD2 or MTHFD2L, is a critical control point for 
mitochondrial 1C metabolism. Using an in silico model, Nijhout et al. (Nijhout et 
al., 2006) observed that the exclusion of CH2-THF dehydrogenase and CH
+
-THF 
cyclohydrolase activities from the mitochondrial folate pathway results in loss of 
formate export and a dramatic increase in mitochondrial serine production for 
gluconeogenesis. When CH2-THF dehydrogenase and CH
+
-THF cyclohydrolase 
activities are included in the model, the mitochondrial folate pathway produces 
formate for cytosolic export, where it is incorporated into purines, thymidylate, 
and the methyl cycle (Nijhout et al., 2006). Christensen and MacKenzie 
(Christensen and MacKenzie, 2006) have proposed that the level of MTHFD2 
expression could act as a metabolic switch to control the balance between serine 
and formate production. 
"We suggest that the existence of two mitochondrial 
dehydrogenase/cyclohydrolase isozymes in mammals (MTHFD2 and MTHFD2L) 
reflects the need to tightly regulate flux through this oxidation step in response to 
changing metabolic conditions and needs. For example, de novo purine 
biosynthesis is especially important in rapidly dividing cells, such as during 
embryogenesis. Thus, early embryos express both MTHFD2 and MTHFD2L 
isozymes, ensuring that mitochondrial formate production is adequate to 
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support de novo purine biosynthesis. Indeed, embryonic growth and neural tube 
closure requires mitochondrial formate production . Compared with embryos, 
however, adult mammals do not have a high demand for de novo purine 
biosynthesis (Alexiou and Leese, 1992). The loss of expression of MTHFD2 as 
the embryos approach birth may reflect the lower demand for de novo purine 
biosynthesis in neonate and adult mammals." 
"In addition to switching between expressing one or two mitochondrial CH2-THF 
dehydrogenase/CH
+
-THF cyclohydrolase enzymes, there may be other ways of regulating 
MTHFD2L expression such as alternative splicing." I report here the relative abundances 
of MTHFD2L splice variants either containing or lacking exons 2 and 8 in mouse 
embryos. The splice variant containing exon 2, which would introduce an early stop 
codon, was at low abundance at all time points examined. We have previously shown that 
the splice variant lacking exon 8 is present in a variety of adult tissues. We show here that 
this splice variant accounts for up to 45% of total MTHFD2L transcripts. Although the 
loss of exon 8 did not appear to affect mitochondrial sublocalization, this splice variant 
was found to be catalytically inactive in vitro and in vivo. Expressing a catalytically 
inactive splice variant may represent one means of regulating dehydrogenase/ 
cyclohydrolase activity in the mitochondria. There is also the possibility that this splice 
variant has a protein binding or structural function that does not require it to be 
catalytically active. A recent study has reported that MTHFD2 localizes to the nucleus 
near sites of DNA synthesis and enhances cell proliferation independently of its catalytic 
activity (Gustafsson Sheppard et al., 2015). Given the sequence similarities between 
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MTHFD2L and MTHFD2, it is possible that a similar function may exist for MTHFD2L 
or its splice variants.   
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Chapter 3: Characterization of loss of function of MTHFD1L in adult 
mice 
3.1 INTRODUCTION 
There has long been a known association between disruptions to folate 
metabolism and cognitive dysfunction (Melamed et al., 1975; Strachan and Henderson, 
1967). Disruptions to folate metabolism can be caused by environmental factors, such as 
folate deficiency, or genetic factors. Undoubtedly, the best characterized folate gene with 
regards to cognitive dysfunction is MTHFR. MTHFR catalyzes the conversion of CH2-
THF to CH3-THF for use in the methyl cycle. A common polymorphism of MTHFR 
(C677T) reduces the enzymatic activity of MTHFR and disrupts the methyl cycle (Frosst 
et al., 1995). Both folate deficiency and mutations in MTHFR have been found to be 
associated with increased risk for Alzheimer's disease, Parkinson's disease, vascular 
dementia, and depression (Bjelland I, 2003; Jadavji et al., 2015; Kim et al., 2008; 
Mattson et al., 1999). 
One of the main culprits implicated in the etiology of diseases caused by either 
folate deficiency or MTHFR mutations is elevated homocysteine (Araújo et al., 2015). 
1C units generated in the mitochondria serve as substrates for synthesis of methionine 
from homocysteine. Methionine, when converted to S-adenosylmethionine in the methyl 
cycle, can serve as a source of methyl groups for DNA methylation, histone methylation, 
and synthesis of neurotransmitters, all of which are important for cognitive function 
(Chiang et al., 1996; Grillo and Colombatto, 2008; Su et al., 2016). Similar to folate 
deficiency and MTHFR mutations, increased homocysteine is an independent risk factor 
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for dementia, Alzheimer's disease, depression, and cardiovascular disease (Araújo et al., 
2015; Bjelland I, 2003; Luchsinger et al., 2004; Refsum et al., 1998; Seshadri et al., 2002; 
Van Dam and Van Gool, 2009). Whether this association is only due to the fact that 
elevated homocysteine is a symptom of altered methionine metabolism or homocysteine 
itself is responsible for the negative effects is still not fully understood. Both cases are 
likely true depending on the situation. For example, folate deficient rats show cognitive 
impairment that can be reversed with methionine supplementation; however, 
homocysteine remains elevated (Troen et al., 2008). In some cases though, homocysteine 
may be directly responsible for neurodegeneration. It has been reported that 
homocysteine induces apoptosis in neurons through DNA damage (Kruman et al., 2000). 
Homocysteine has also been shown to sensitize hippocampal neurons to amyloid toxicity 
in a mouse model of Alzheimer's disease (Kruman et al., 2002). 
Although MTHFR is the most commonly studied folate-related gene in regards to 
cognitive dysfunction, recent studies have implicated MTHFD1L as well. Three 
independent studies have identified a single nucleotide polymorphism (SNP, rs11754661) 
in the gene encoding MTHFD1L that is associated with increased risk for late onset 
Alzheimer's disease (LOAD), but the underlying mechanisms have not yet been 
identified (Ma et al., 2012; Naj et al., 2010; Ramírez-Lorca et al., 2011; Ren et al., 2011). 
The same SNP has also been implicated in increased rumination in patients with major 
depressive disorder (Eszlari et al., 2016). Because mitochondrial MTHFD1L provides 1C 
units to the cytoplasm for methionine synthesis from homocysteine (Pike et al., 2010), we 
hypothesize that loss of MTHFD1L activity could result in elevated homocysteine and 
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altered cellular methylation leading to downstream effects on behavior and memory in 
mice.  
In this chapter, I investigate the loss of MTHFD1L in adult mice in conjunction 
with a folate deficient diet using experiments designed to test for anxiety-related 
behaviors and memory defects. I also examine alterations in methyl cycle metabolites in 
serum and brain tissue. 
3.2 MATERIALS AND METHODS 
3.2.1 Mouse Work 
All protocols used within this study were approved by the Institutional Animal 
Care and Use Committee of The University of Texas at Austin and conform to the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice 
were maintained on the C57BL/6 background. Genotyping was carried out using a 
modified PCR method (Stratman et al., 2003). A forward primer (5′-
GAGTATGTGATTGCTTGGACCCCCAGGTTCC-3′) binding in the 5' region outside 
of the floxed cassette (see below) and reverse primer (5′-
TGGCTCCCGAGGTTGTCTTCTGGCTATGAT-3′) binding 5' to exon 5 within the 
floxed cassette would yield a 444-bp amplicon for the wild-type allele, a 543-bp 
amplicon for the floxed allele, and no product when the conditional cassette was 
removed. Cre recombinase was detected using the forward 
(GCATTACCGGTCGATGCAACGAGTGATGAG-3') and reverse 
(GAGTGAACGAACCTGGTCGAAATCAGTGCG-3') primers which yield a 408-bp 
amplicon.  
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For the preliminary study, MTHFD1L mutant mice (see below) were treated after 
weaning with 1 mg tamoxifen per day by gavage for 5 days. Mice were maintained on 
standard chow for the duration of the study. Experiments were started after the mice 
reached approximately 1 year of age. In the main study, mice aged 1.5-3 months old were 
placed on a diet containing 333mg/kg tamoxifen (Harlan Teklad, TD.09548) for 1 month. 
After tamoxifen treatment, mice were started on either control (CD) or folate deficient 
diets (FD) (Harlan Teklad, TD.04194 and TD.95247 respectively). The diets were 
identical except that CD contained 2 mg/kg folic acid and FD did not contain any folate. 
3 months later, behavioral testing was started. Mice were euthanized at approximately 10-
11 months of age. Serum was collected by cardiac puncture, and brain, liver, and spleen 
tissues were rinsed with PBS and stored at -70
o
C. 
3.2.2 MTHFD1L conditional knock out 
Because homozygous deletion of MTHFD1L is embryonic lethal (Momb et al., 
2013), we generated a conditional knockout to study loss of MTHFD1L in adult mice. A 
mouse line containing a conditional cassette consisting of loxP sites on either side of 
exon 5 of Mthfd1l in both alleles was bred with mice expressing Cre-ERT2 under control 
of the ubiquitin C promoter. Cre-ERT2 is a fusion protein of Cre recombinase and a 
mutant form of the estrogen receptor (ER) that is activated by tamoxifen but is not 
affected by estrogen (Feil et al., 1997). When activated by tamoxifen, Cre-ERT2 will 
translocate into the nucleus and recombine out the region between the two loxP sites. 
Deletion of exon 5 introduces a frame shift that disrupts translation of the rest of the 
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protein. Mice containing the floxed alleles and expressing Cre-ERT2 will be referred to 
as "mutant" mice and control mice containing the floxed alleles but lacking Cre-ERT2 
will be referred to as "WT" in the following work.  
3.2.3 Behavioral experiments 
Mice were brought to the testing room at least one hour prior to each experiment 
to be allowed to acclimate to the testing environment. During each experiment, 
movement was recorded with a digital camera. Movement data was analyzed using the 
Any-maze software (Stoelting Co.; Wood Dale, IL). 
3.2.3.1 Open Field Test 
 The testing chamber consisted of a 40 x 40 cm box. The walls were made of 35 
cm high opaque plastic. The chamber was lit from above by a diffuse light source. To 
initiate the test, mice were placed in a corner of the testing chamber facing the outer wall. 
Mice were observed for 30 minutes. The center was defined as an 18.5 x 18.5 cm zone in 
the center of the chamber. 
3.2.3.2 Elevated Plus 
The plus-shaped maze consisted of four arms each 30 cm in length and 5 cm in 
width. Two arms were "closed" with walls 13 cm in height, and the other two arms were 
"open." The maze was on a stand set approximately 130 cm above the floor. The maze 
was lit from above with a diffuse light source. Mice were placed in the one of the closed 
arms facing the outside of the apparatus to begin the test. Mice were observed for 10 
minutes. 
 52 
3.2.3.3 Delay Fear Conditioning 
The testing chamber consisted of a box lit with a white light and a metal grate for 
the floor. The back of the box contained an infrared camera to track the movement of the 
mice. After cleaning the box with a Clorox wipe, the box was wiped with ethanol. The 
fear conditioning procedure took place over three days. Freezing behavior was scored 
using a pixel-change algorithm (VideoFreeze, Med Associates Inc., St. Albans, VT).  
Day 1 - Cue and context fear conditioning  
Mice were placed in the testing chamber and the testing procedure was initiated. 
The testing procedure began with a 120 second pre-tone habituation period followed by 
four tone-shock pairings occurring at 120, 204, 314, and 409 seconds. Each tone-shock 
pairing consisted of a 20 second tone (CS, 5000 Hz, 85 db) with a 1 second shock (US, 
0.75 mA) during the final second of the tone.  
Days 2 and 3 - Context and Cue testing 
On day 2, one randomly selected group of mice was tested for context-dependent 
fear conditioning, and the other group was tested for cue-dependent conditioning. On day 
3, the groups were switched. For the context test, mice were placed in a chamber identical 
to the chamber on day 1. Freezing was measured for 5 minutes in the absence of any 
tones or shocks. For the cue test, the testing chamber was altered to have an uneven grate 
for the floor, a triangular roof insert, the white light was turned off, and the chamber was 
wiped with acetic acid instead of ethanol. During the test, tones identical to those played 
on day 1 were played at the same intervals but without the shocks.  
3.2.3.4 Morris Water Maze 
Mice were first pre-trained to locate the platform beneath the surface of the water. 
A small bucket was filled with water (21
o
C) and a circular platform (8 cm in diameter) 
was submerged 1 cm beneath the surface. The water was made opaque with white 
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tempera paint. Mice were placed on the platform for 10 seconds. If the mice jumped off 
of the platform, they were guided back to the platform by hand. This procedure was 
carried out three times a day for three consecutive days. After each trial, the mice were 
dried with paper towels and placed in a cage warmed with an infrared heating lamp and a 
heating pad.  
Hidden platform training was started one week after the first day of pre-training. 
A circular tank 120 cm in diameter was filled with water (21
o
C) made opaque with 
tempera paint. The platform was submerged 1 cm below the surface in the center of one 
of four quadrants of the tank. The tank was surrounded by black curtains, and each 
quadrant had a different object that varied in shape, size, and color affixed to the curtain. 
At the beginning of each trial, the mouse was placed in the tank near the wall in one of 
the four quadrants. The trial would last for two minutes or until the mouse reached the 
hidden platform. If the mouse was unable to find the platform after two minutes, the 
mouse would be guided by hand to the platform. Four trials per mouse were conducted 
each day for five consecutive days. The starting location for each subsequent trial was 
moved to a different quadrant each time. One week after the start of training, the mice 
were subjected to a two minute probe trial, in which the platform was removed.  
3.2.4 Immunoblotting 
Mitochondria were isolated from brain tissue as previously described (Pike et al., 
2010). Protein concentration was determined by BCA assay (Thermo Fisher Scientific). 
Proteins were separated by SDS-PAGE and immunoblotted using rabbit polyclonal anti-
MTHFD1L (1:1,000) (Prasannan and Appling, 2009). After incubation with HRP-
conjugated goat anti-rabbit IgG (1:5,000) (Invitrogen), reacting bands were detected 
using ECL Prime (GE Healthcare Life Sciences).  
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3.2.5 Statistics 
Unpaired t-tests were performed in Microsoft Excel. All other analyses were 
performed with JMP Pro 12 (SAS Institute). Grouped data was analyzed by two-way 
ANOVA, and Tukey's HSD test was used for post hoc pairwise comparisons. The mixed-





3.3.1 Preliminary Study  
A small pilot study consisting of 8 mutant and 6 WT mice was conducted to 
assess the effects of loss of MTHFD1L in adult mice. The mice were subjected to a 
battery of tests designed to assess anxiety-like behavior and memory. The open field test 
and elevated plus maze were used to evaluate spontaneous exploration and anxiety-like 
behavior (Denenberg, 1969; Hogg, 1996; Pellow et al., 1985). In the open field test, mice 
are placed in a box with high walls that is open to the ceiling. The elevated plus maze 
consists of four arms elevated above the ground. Two of these arms are enclosed by walls 
and the other two are completely open. Mouse movements are tracked by a digital camera 
and the time spent and distance travelled in open versus closed areas are compared. Mice 
have an innate exploratory drive but also tend to avoid open spaces, and these tests 
evaluate the competition among these two drives. Mouse models of AD have shown 
increased exploratory behavior (Bryan et al., 2009). 
In the pilot study, the open field test seemed to indicate the mutant mice were 
more active, with a trend for them to travel a longer total distance during the test (Figure 
3.1). Though mutant mice travelled the same distance through the center as WT mice, 
they spent less time in the center (Figure 3.1). This means that though mutant mice did 
venture into the center of the field, they traversed more quickly than WT mice, possibly 
indicating an anxiety phenotype. A similar anxiety phenotype was seen in the elevated 
plus maze, with Mutant mice spending less time and travelling a shorter distance on the 
open arms (Figure 3.1).  
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Delay fear conditioning and the Morris water maze were used to test associative 
and spatial memory in these mice. Fear conditioning is a Pavlovian learning task in which 
mice learn to associate a conditioning stimulus (CS), like a tone, with an aversive 
unconditioned stimulus (US), such as a foot shock, that takes place immediately after the 
CS. After being trained to associate the US with the CS, mice can be exposed to either 
the CS alone (alternate context) or the context (lighting, shape of the enclosure, smells, 
etc.) in which they experienced the US, and fear response, as indicated by freezing 
behavior, can be observed. Lesions in the amygdala have been shown to prevent 
association of the US with the CS, while lesions in the hippocampus prevent association 
of the US with the context in which the US is delivered (reviewed in (Maren, 2001)). 
Atrophy of both the amygdala and the hippocampus have been associated with AD 
(Chow et al., 2012; Poulin et al., 2011). We did not observe any significant differences 
during training, but mutant mice in the context test showed higher freezing early in the 
test, possibly indicating increased anxiety. Overall there were no significant differences 
in the alternate context test, but mutant mice showed a trend towards decreased pre-tone 
freezing (Figure 3.2).  
The Morris water maze is a spatial learning test that was first described by Morris 
(Morris, 1984). In this test, mice are placed in a large water tank containing a single 
platform just beneath the surface of the water. The water is made opaque so that the 
platform cannot be seen, and mice must rely on external visual cues to orient themselves 
in relation to the platform's location. Mice are trained with multiple trials per day over 
several days (acquisition) to learn the location of the platform. After acquisition training, 
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mice are tested in a probe trial in which the platform is removed and the number of times 
the mice cross the area where the platform used to be is recorded (real platform). The 
number of crossings of an area the same size as the platform in the opposite quadrant of 
the tank (false platform) is measured as a negative control. If the mice learn and 
remember the location of the platform, they will be expected to cross the real platform 
more frequently than the false platform. Folate deficiency Mice were trained with 4 trials 
per day for 5 days. There was a trend for mutant mice to acquire the platform's location 
more slowly than WT (p = 0.25, Figure 3.3). In the probe trial, WT mice crossed the real 
platform location significantly more frequently than the false location (p = 0.039), 
whereas mutant mice did not (p = 0.61) (Figure 3.3).  
The pilot study suggested some interesting potential changes in mice with 
decreased MTHFD1L activity, but many of the trends we observed were not statistically 
significant. We speculated that this could be due to one or more of several factors. First, 
the number of mice used may have been too small to have sufficient power to detect the 
behavioral differences in the mice. Second, though there was no detectable expression of 
MTHFD1L in brain tissue, several tissues retained expression of MTHFD1L (not shown). 
It has been reported that in conditional knockouts using the Cre-ERT2 system, expression 
of the target gene can recover over time, especially in proliferative tissues (Ruzankina et 
al., 2007). It is possible that the long delay between tamoxifen treatment and the start of 
the experiments allowed enough recovery of MTHFD1L expression to rescue some of 
behavioral alterations. A final possibility is that differences we saw were artifacts caused 
by the low number of mice used in the study. With these factors in mind, we planned a 
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larger scale follow-up study. This study would consist of approximately 60 total mice, 30 
WT and 30 mutant. Half of these mice (15 WT and 15 mutant) would be placed on a 
folate deficient diet with the intent of exacerbating any potential phenotype associated 
with loss of MTHFD1L. Finally, the behavioral experiments would be conducted much 
sooner after tamoxifen treatment. The rationale was that if the behavioral alterations are a 
result of metabolic changes caused by loss of MTHFD1L, conducting the experiments 
before expression of MTHFD1L had a chance to recover may improve our chances of 






































Figure 3.1  Preliminary results of open field and elevated plus tests. In the open field 
test (A-C) mutant mice showed a trend for a longer total distance and 
moving through the center more quickly. In the elevated plus maze (D,E), 



























































































































Figure 3.2  Preliminary fear conditioning. (Top) Context test. Test was conducted in the 
same context as the tone-shock training. * indicates p < 0.05 for that time 
point. (Bottom) Pre-tone freezing in alternate context test. Test was 
conducted in a different context from tone-shock training (different floor 
shape, roof shape, scent, and lighting). Error bars in both graphs represent 

























































Figure 3.3 Preliminary results of Morris water maze. (Top) Hidden platform training. 
Each point represents the mean time required to find the hidden platform. 
Error bars represent +/- SEM. (Bottom) Probe Trial. Bars represent mean 
number of entries into real or false platform area +/- SEM.  
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3.3.2 Main Study 
3.3.2.1 Open Field Test 
Mice were first tested on the open field apparatus (Figure 3.4). An initial 3 way 
ANOVA showed there was a sex effect where female mice travelled a longer total 
distance (p = 0.008), distance along the margin (p = 0.0015), and distance through the 
center (p = 0.026), so results from male and female mice were analyzed separately. 
Mutant male mice appeared to be more active than male WT mice, travelling a longer 
total distance independently of diet (p = 0.012). There was no significant difference in 
total distance in female mice. Female mice on the FD tended to spend more time on the 
margin of the apparatus (p = 0.015) and there was a trend for a shorter distance travelled 
through the center (p = 0.074) (center distance was corrected for the total distance 
travelled). There were no significant effects in male mice for time spent on the margins or 
distance travelled through the center.  
3.3.2.2 Elevated Plus 
Next, mice were tested on the elevated plus maze (Figure 3.5). We did not 
observe any significant differences in time spent or distance travelled on either the open 
or the closed arms of the maze, nor did the total distance travelled during the test 
significantly differ with regards to sex, diet, or genotype.  
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3.3.2.3 Delay Fear Conditioning 
On the first day of the fear conditioning experiment, the mice were trained to 
associate a foot shock with a tone. The tone plays for 20 seconds with the foot shock 
applied during the last second of the tone. There were four of these tone-shock pairings 
during the course of the approximately 8 minute training period. The average freezing 
during the pre-tone period and during each tone was examined (Figure 3.6). We found a 
significant sex x time interaction (p = 0.0351), so results from male and female mice 
were analyzed separately. In both male and female mice, freezing behavior changed 
significantly over time (p < 0.0001). In male mice, there was a significant genotype x 
time interaction (p = 0.0123), but female mice only showed a significant diet effect (p = 
0.0218), with female mice on the FD exhibiting higher freezing. 
Over the next two days, mice were tested for context-dependent and cue-
dependent (alternate context) fear conditioning. We did not observe any significant 
effects due to diet, sex, or genotype in the context test (Figure 3.7). In the alternate 
context test, freezing increased over time in response to the CS (p < 0.001), but freezing 
did not significantly differ between groups (Figure 3.8). 
3.3.2.4 Mouse weights and immunoblots 
At the conclusion of behavioral experiments, mice were weighed prior to 
dissection and tissue collection (Table 3.1). Male mice weighed more than female mice 
(p < 0.0001), but weights were not significantly affected by genotype or diet. 
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Mitochondria were isolated from brain tissue and an immunoblot for MTHFD1L 
expression was performed on mitochondrial extracts. MTHFD1L expression was 
markedly decreased in CD mutant mice, though some mice still retained a degree of 
MTHFD1L expression (Figure 3.9). Surprisingly, mutant mice on the FD appeared to 
retain much more expression of MTHFD1L than mutant mice on the CD. 
3.3.2.5 Serum and brain metabolites 
Whole brain samples (one hemisphere) and serum samples were analyzed to 
determine the concentrations of folate and metabolites related to the methyl cycle 
(Bottiglieri Lab, UT Southwestern). 5-CH3-THF and homocysteine (Hcy) were measured 
in serum; and methionine, S-adenosylmethionine (SAM), S-adenosylhomocysteine 
(SAH), cystathionine, betaine, and choline were measured in brain tissue. Male and 
female mice seemed to respond differently to both loss of MTHFD1L and the effects of 
the folate deficient diet. Female mice on the FD had significantly lower 5-CH3-THF in 
serum (p < 0.0001, Figure 3.10). Although there was no significant genotype effect on 5-
CH3-THF levels in female mice, there was a significant diet x genotype interaction (p = 
0.0148). Male mice on the FD also had lower 5-CH3-THF in serum (p < 0.0001, Figure 
3.10), but there was also a genotype effect where male mutant mice on the CD had lower 
5-CH3-THF than WT mice on the CD (p = 0.0257, Figure 3.10). Serum homocysteine in 
female mice showed a trend for a diet x genotype interaction (p = 0.094), but post hoc 
analysis did not show any significant differences between groups (Figure 3.10). Hcy was 
elevated in response to both the mutant genotype (p = 0.0145) and FD (p = 0.001) in male 
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mice; however, post hoc pairwise comparisons indicated that only mutant mice on the FD 
significantly differed.  
Genotype did not appear to have any significant effects on the metabolites 
measured in brain tissue; however, several were altered in response to the FD. In the 
brain tissue of female mice, methionine was the only metabolite to significantly differ (p 
= 0.0007), decreasing in mice on the FD (Table 3.2). In male mice, methionine was 
unchanged, but SAM increased (p = 0.0425) and SAH decreased (p = 0.010) in mice on 
the FD (Table 3.3). There was also a decrease in choline (p = 0.0007) in male mice on the 



































Figure 3.4 Open field test. Where significant differences were found either based on 
genotype or diet, Tukey's test was used for post hoc pairwise comparisons. 
Bars that share the same letter do not significantly differ. Where letters are 
omitted, no significant differences were found in the post hoc analysis. Bars 













































































































































































































































































































































Figure 3.6  Fear conditioning training. Each point represents mean % freezing for a 10 
second time bin. Error lines represent SEM. Vertical grey bars indicate tone 
periods and vertical black lines represent the foot shock. Mice of the same 
sex were analyzed together but have been separated here by diet for ease of 
viewing. 
  



































































































































Figure 3.7 Fear conditioning context test. Test was conducted in the same context as 
the tone-shock training. Bars represent mean % freezing over 5 minute 

























































Figure 3.8  Fear conditioning alternate context test. Test was conducted in a different 
context from tone-shock training (different floor shape, roof shape, scent, 
and lighting). Each point represents mean % freezing for a 10 second time 
bin. Error lines represent SEM. Vertical grey bars indicate tone periods. 
Mice of the same sex were analyzed together but have been separated here 
by diet for ease of viewing. 
 
  

































































































































 Folate Deficient Diet 
 
Figure 3.9  Representative immunoblots of MTHFD1L expression in the brains of mice 
on control and folate deficient diets.  
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Figure 3.10  Serum 5-CH3-THF and homocysteine. Where significant differences were 
found either based on genotype or diet, Tukey's test was used for post hoc 
pairwise comparisons. For each metabolite, identical letters over two bars 
signify that those samples do not significantly differ (e.g. 5-CH3-THF in 
female WT-FD and Mutant-FD mice does not significantly differ). Bars 
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Table 3.1  Numbers and weights of mice used in study. The number of mice in each 




Female CD FD 2-way ANOVA P-value 




















3.0 0.953 0.143 0.974 
SAH (nmol/g) 4.5 ± 1.0 4.1 ± 0.3 4.6 ± 1.1 3.9 ± 0.6 0.103 0.939 0.557 
























102 263 ± 87 265 ± 75 255 ± 53 0.882 0.920 0.862 
 
Table 3.2 Methyl cycle metabolites from the brains of female mice.  
 75 
Male CD FD 2-way ANOVA P-value 




















3.5 0.975 0.026 0.993 
SAH (nmol/g) 5.0 ± 0.9 4.7 ± 0.7 4.2 ± 0.8 
4.0 ± 







































64b 0.750 <0.001 0.027 








We report here a model of the loss of MTHFD1L in adult mice. While there were 
no major changes to the behavior or memory of the mice, there were some subtle 
differences in how male and female mice responded to the folate deficient diet (FD) and 
loss of MTHFD1L. Female mice appeared to be more affected by the folate deficient diet, 
with female mice on the FD appearing to show an aversion to open spaces in the open 
field test, and showing higher freezing during the training period of the delay fear 
conditioning experiment. Male mice did not show any diet-dependent effects in the 
behavioral experiments; however, male mutant mice appeared to be more active in the 
open field test than WT, and there was a significant genotype x time interaction during 
the training period in the fear conditioning test. Sex-dependent effects have been reported 
in other models of folate metabolism dysfunction. A study looking at 
methylenetetrahydrofolate reductase (MTHFR) heterozygote mice found that male 
MTHFR heterozygotes were hyperactive during the open field test, but female mice were 
not (Levav-Rabkin et al., 2011). This is reminiscent of the increased activity of male 
mutant mice in the open field test that we have observed, but the lack of increased 
activity in the elevated plus maze makes it difficult to draw any firm conclusions. A 
similar increase in activity without an increase in anxiety has been seen in mice fed a diet 
deficient in choline and vitamins B2, B9, B12, though no sex-dependent differences were 
reported (Lalonde et al., 2008). Another study found that homocysteine concentrations in 
patients with the MTHFR C>T genotype was associated with interactions between 
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genotype and folate status in males but only folate status in females (Stanisławska-
Sachadyn et al., 2008).  
In addition to the sex-dependent behavioral differences, we also observed 
different sex-dependent responses to genotype and diet effects on serum 5-CH3-THF and 
homocysteine. While both male and female mice had lower 5-CH3-THF on the FD, only 
male mutant mice on the CD had significantly lower 5-CH3-THF than WT. Additionally, 
male mice appeared to be more susceptible to increased serum homocysteine, with 
homocysteine increasing due to both genotype and diet. These results were unexpected, 
as folate deficiency is typically reported to increase homocysteine in both male and 
female mice (Jadavji et al., 2015; Martínez-Vega et al., 2016). Also unexpected, was our 
finding that brain SAM/SAH increased on the FD in male mice, despite the rise in serum 
homocysteine. Typically an increase in serum homocysteine is accompanied by a 
decrease in SAM/SAH (Chen et al., 2001; Yi et al., 2000). Increased serum homocysteine 
in male mice may provide an explanation for the apparent hyperactivity in male mice 
during the open field test; high homocysteine has been associated with hyperactivity in 
various mouse models (Lalonde et al., 2008; Middaugh et al., 1976), but it is unclear how 
this could be reconciled with the increase in brain SAM/SAH.  
This study had several limitations. First, the tamoxifen treatment to knock down 
expression of MTHFD1L was not done until after weaning, so any deleterious effects 
caused by MTHFD1L dysfunction during development would not be seen in these 
experiments. Since deletion of MTHFR is not lethal, studies looking at the effects of 
MTHFR deletion on behavior do not have this limitation (Jadavji et al., 2012; Levav-
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Rabkin et al., 2011). Due to the embryonic lethality caused by complete loss of 
MTHFD1L, the homozygous deletion of the gene during development is not feasible for 
studies of adult mice; however, the use of a mouse expressing Cre recombinase under the 
control of a tissue specific promoter may allow embryos to survive until birth. Another 
option is to use MTHFD1L heterozygotes, which are viable and have been shown to 
express lower levels of the MTHFD1L protein as embryos (Momb et al., 2013). Another 
limitation is that the knockdown of MTHFD1L was variable and incomplete, especially 
in the FD mice. This could be due to incomplete knockdown from the initial Tamoxifen 
treatment, or the subsequent recovery of expression of MTHFD1L over time after 
Tamoxifen treatment. Because the degree of Tamoxifen exposure is dependent on how 
much of the diet is consumed, the actual Tamoxifen dosage for each mouse could be 
highly variable. Administering the Tamoxifen by gavage would provide a more 
consistent means of treating the mice. Recovery of expression of MTHFD1L over time 
could also cause inconsistencies between mice. Recovery of the expression of the target 
gene in conditional knockdowns using the Cre-ERT2 system, particularly in proliferative 
tissues, has been reported (Ruzankina et al., 2007). One strategy to minimize this effect 
would be to use mice that are heterozygous-null for MTHFD1L, with the other allele 
containing the floxed exon. Since only one allele per cell would need to be recombined 
by Cre recombinase, the chances of getting a complete knockout of MTHFD1L would be 
increased. It is unclear why expression of MTHFD1L would be higher in mutant mice on 
the FD than mutant mice on the CD. Since mice were not placed on the FD until after the 
Tamoxifen treatment, the higher level of MTHFD1L expression is likely due to recovery 
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of expression of MTHFD1L rather than a difference in the efficiency of the initial 
knockdown.  
We did not detect any deficits in cue or context dependent memory due to either 
diet or genotype; however, more stringent experiments may have revealed effects not 
tested by delay fear conditioning. Trace fear conditioning, where there is a short period of 
time between the conditioned stimulus and the unconditioned stimulus, may reveal 
differences between groups that are not apparent with delay fear conditioning. For 
example, hippocampal lesions may only result in deficits in trace, but not delay, fear 
conditioning (James et al., 1987; McEchron et al., 1998, 2000; Quinn et al., 2002). In 
addition, trace fear conditioning has been shown to require higher cognitive functions, 
such as awareness or attention, that are not required for delay fear conditioning (Clark 
and Squire, 1998; Han et al., 2003; Weike et al., 2007). Another alternative is the Morris 
water maze. Mice in the main study were not tested on the water maze due to time and 
budgetary constraints. The Morris water maze could reveal deficits in spatial learning and 
memory that are not tested in fear conditioning experiments (reviewed in (Vorhees and 
Williams, 2014)). Finally, older mice than those used in this study may have additional or 
more severe phenotypes than those observed in the current study.   
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Chapter 4: Metabolic characterization of MTHFD1L null embryos 
4.1 INTRODUCTION 
Neural tube defects have a complex etiology, involving both environmental and 
genetic factors. The link between low folate status in pregnant women and risk of NTDs 
was first recognized in the 1960s and 1970s (Hibbard, 1964, 1967; Smithells et al., 1976). 
Since then, maternal supplementation with folic acid has been shown to reduce NTDs by 
as much as 70% (MRC Vitamin Study Research Group, 1991), but this still leaves 30% 
of NTD cases that are resistant to folic acid supplementation. Understanding the role of 
folic acid in neural tube closure is important for learning how folate supplementation 
prevents NTDs and why some NTDs are resistant. An essential tool for studying NTDs is 
mutant mouse models that develop NTDs; however, only a handful of null mutants of 
folate-related genes form NTDs (Harris and Juriloff, 2010). Mice lacking either Folr1 or 
Shmt1 both develop NTDs that are sensitive to folate status (Anderson and Stover, 2009; 
Beaudin et al., 2011; Piedrahita et al., 1999; Spiegelstein et al., 2004). Deletion of Amt or 
Gldc in mice also results in NTDs, but these mice do not respond to folic acid (Narisawa 
et al., 2012; Pai et al., 2015). If the mechanisms in these mice, or other folate resistant 
mouse models, leading to NTDs are better understood, therapies could be developed to 
prevent NTDs that are resistant to folic acid in humans. 
Metabolomic profiling has been used to identify metabolic defects in several 
mouse models of NTDs. Mice nullizygous for LRP6 develop exencephaly and spina 
bifida (Pinson et al., 2000). LRP6 mutants were found to have decreased concentrations 
of the methyl cycle metabolites methionine, homocysteine, and, SAH. The purine base 
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hypoxanthine was also decreased (Hansler et al., 2014). A study looking at valproate-
induced NTDs in mice found that a range of purines and pyrimidines were decreased, and 
the methyl cycle/1C metabolites methionine, SAM, SAH, serine, and glycine were all 
reduced (Akimova et al., 2016). Another study has profiled folate species in GLDC-null 
mice, and found an increase in free THF and DHF accompanied by a decrease in 5-CH3-
THF. The same mice also had significantly increased levels of glycine (Pai et al., 2015). 
Our lab has previously reported a mouse model containing a homozygous deletion 
of MTHFD1L. Embryos lacking MTHFD1L were found to exhibit aberrant neural tube 
closure, craniofacial defects, developmental delay, and embryonic lethality by embryonic 
day 12.5 (E12.5) (Momb et al., 2013). The aberrant neural tube closure occurs with 100% 
penetrance without feeding a folate deficient diet and includes defects such as wavy 
neural tube, exencephaly, and craniorachischisis. Treating the mice with folinic acid (5-
CHO-THF) had no effect on the incidence of neural tube defects (Jessica Momb, 
unpublished data). This result makes intuitive sense, because if the protein MTHFD1L is 
missing, adding additional cofactor will have no effect on the missing enzymatic activity. 
The lack of 10-CHO-THF synthetase activity is expected to result in a loss of 
mitochondrial production of formate, so pregnant dams were supplemented with formate. 
We found that maternal supplementation with sodium formate reduced the incidence of 
neural tube defects, partially rescued the growth restriction, and allowed survival past the 
previous point of lethality. It has since been found that rescue with formate occurs in a 
dose dependent manner. Embryos at E15.5 were dissected from a series of matings in 
which the dams were supplemented with a calculated dose of either 250, 500, 1,500, 
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2,500, or 3,500 mg⋅kg−1⋅d−1 calcium formate. Mthfd1lz/z embryos were observed at all 
doses of calcium formate, and the number of embryos did not significantly differ from 
the expected Mendelian ratio. The crown-rump length of Mthfd1l
z/z
 embryos increased 
significantly at the 1,500 and 2,500 doses. As the dose of formate increased, up to 2,500 
mg⋅kg−1⋅d−1, there was a concomitant increase in the proportion of Mthfd1lz/z embryos 
observed which did not have any obvious morphological defects (Jessica Momb, 
unpublished data). 
Despite these results, the exact metabolic defects caused by loss of MTHFD1L 
that could be leading to NTDs remain unknown. Given the role of MTHFD1L in 
generating 1C units for cytoplasmic synthetic reactions, I hypothesize that metabolism of 
purines, thymidylate, and methionine will be disrupted by loss of MTHFD1L and that 
formate supplementation will rescue that disruption. In this chapter, I investigate formate 
production from mitochondria missing MTHFD1L and identify metabolic defects 
associated with loss of MTHFD1L that could contribute to the occurrence of NTDs.  
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4.2 MATERIALS AND METHODS 
4.2.1 Mice and Formate Supplementation 
All protocols in this study were approved by the Institutional Animal Care and 
Use Committee of The University of Texas at Austin and conform to the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals. Mice were 
maintained on a C57BL/6 background. 
 Where indicated, matings of Mthfd1l
z/+
 mice were set up in cages equipped with 
a water bottle containing calcium formate. The concentration of calcium formate was 
adjusted to deliver a calculated dose of 2,500 mg⋅kg-1⋅d-1 based on the assumption that a 
25 g C57BL/6 mouse consumes water at a rate of 5 mL/d(Whiting et al., 1991). The 
female mice had access to the supplemented water a minimum of one day prior to the 
observation of a vaginal plug. 
4.2.2 Cell Lines and Media 
Wild type and nullizygous MTHFD1L MEFs were derived as described below. 
The cell lines were not immortalized, so all experiments were conducted low passage 
numbers (fewer than four passages). Cells were grown in either DMEM (Sigma) 
supplemented with 10% Fetal Bovine Serum (FBS) or MEM (MP Bio 1641454) 
supplemented with 15% dialyzed FBS. Cells were grown in a humidified cabinet at 37
o
C 
under 5% CO2 on 100 mm dishes. Cells were typically passaged at 95% confluency at no 
more than a 1:4 dilution.  
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4.2.3 Mitochondrial Formate Synthesis Assay 
Due to the requirement for large amounts of mitochondria for this assay, pregnant 
dams were supplemented with 2,500 mg/kg calcium formate to allow survival of 
Mthfd1l
z/z
 embryos past the typical point of lethality at E12.5. Embryos were dissected 
between E14.5 and E16.5. The embryos were genotyped using yolk sack tissue as 
previously described (Momb et al., 2013). Embryos of the same genotype were pooled 
and mitochondria were isolated using differential centrifugation as previously described. 
Mitochondrial protein content was quantified by BCA assay (ThermoFisher Scientific). 
Measurement of mitochondrial synthesis of formate from serine was carried out 
essentially as described previously (García-Martínez and Appling, 1993). In short, 1mg 





dpm/nmol, Moravek Biochemicals, Brea, CA) at the indicated concentration in a shaking 
incubator for 20 minutes at 37
o
C. The reactions were quenched by centrifugation at 
10,000xg at 4
o
C for 10 minutes to remove the mitochondria. The resulting supernatant 
was incubated at 95
o
C to remove any 
14
C labeled CO2 that may have been formed. 
4.2.4 MEF Derivation 
Mouse embryonic fibroblasts (MEFs) were derived essentially as described in (E 
Michalska, 2007). Dams that had been supplemented with a calculated dose of 2,500 
mg/kg calcium formate were euthanized at E14.5 with CO2 asphyxiation followed by 
cervical dislocation. The mice were thoroughly sprayed with 70% ethanol then moved to 
a laminar flow cabinet for dissection. The uterus was dissected and washed with sterile 
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PBS. Individual embryos were placed into separate wells of a 6 well plate containing 
PBS. The yolk sac was saved separately for genotyping. Using two pairs of fine forceps, 
the heads were removed along with the heart and liver. The remaining tissue was moved 
to a 15 mL tube containing 3 mL Trypsin-EDTA (0.25%) and kept overnight at 4
o
C. The 
next morning, most of the Trypsin was aspirated off, leaving about twice the volume of 
the tissue. The tubes were placed at 37
o
C for 30 minutes to activate the Trypsin. 8 mL of 
DMEM (10% FBS, Pen/Strep) was added and the tissue was thoroughly disrupted by 
pipetting. Large pieces of tissue were allowed to sediment for 1 minute, then the 
supernatant was moved to a new tube. 6 mL of media was added to sedimented tissue and 
the disruption and sedimentation were repeated. This supernatant was combined with the 
original supernatant then was distributed onto 5 100 mm plates and incubated at 37
o
C and 
5% CO2. These cells were considered passage number 0. After isolation, MEFs were 
genotyped as described previously (Momb et al., 2013). MEFs were tested for 
mycoplasma infection using a PCR test kit (SouthernBiotech). Expression of the 
MTHFD1L protein was determined by immunoblotting. Proteins were extracted by 
disrupting cells with NP-40 lysis buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, pH 7.5). 
Proteins were separated by SDS-PAGE and immunoblotted as described previously (Pike 
et al., 2010). Blots were probed with anti-MTHFD1L (Prasannan and Appling, 2009) 
(1:1000) and reacting bands were detected with ECL Prime (GE Healthcare Life 
Sciences). 
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 MEFs were plated onto six 96 well plates (one for each 
time point) at a density of 5 x 10
3
 cells per well with four replicate wells per genotype for 
each condition tested. Basal media (referred to as MEM) was made from a formulation of 
Modified Eagle's Medium lacking methionine, cysteine, and cystine (MP Bio 1641454) 
and contained additional 15% dialyzed FBS, 500 μM serine, 20 μM methionine, and the 
following amino acids: 25 mg/L alanine, 50 mg/L asparagine, 30 mg/L aspartate, 75 
mg/L glutamate, 292 mg/L glutamine, 40 mg/L proline, 100 mg/L cysteine, 31 mg/L 
cystine. Additional 30 μM hypoxanthine, 30 μM thymidine, or 1 mM sodium formate 
were added as indicated. Cell growth was monitored using the cell viability assay Cell 
Titer Blue (Promega). 
4.2.6 Methanol Chloroform Extraction of Polar Metabolites 
Prior to starting the extraction, solutions were prechilled in a -80
o
C freezer for 30 
minutes. Embryos or cells were suspended in 1 mL of a 1:1 water:methanol solution and 
were disrupted by pipetting. The lysate was added to a 2 mL glass vial containing 500 μL 
choloroform and vortexed for 20 minutes. Glass vials were centrifuged at 6,000 x g for 
20 minutes at 4
o
C. The upper aqueous phase containing the polar metabolites was 
transferred to a 1.5 mL tube using a Hamilton syringe. Samples were desiccated until 
dryness in a Centrivap vacuum concentrator at 4 C (Labconco, Kansas City, MO, USA), 
then re-suspended in 150 µL of water with 0.1% FA and filtered through a Nanosep 3K 
ultra centrifugal filter (Pall Co. Port Washington, NY, USA) at 8000 rpm for 2 h at 4 C. 
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4.2.7 Embryo Metabolite Analysis 
4.2.7.1 LC-MS 
Chromatographic separation was performed on a Thermo Scientific (Thermo 
Fisher Sci., San José, CA, USA) Accela HPLC system equipped with a quaternary pump, 
vacuum degasser and an open autosampler with a temperature controller. Separation of 
metabolites was achieved through a 100 ×2.1 mm i.d., 2.6 µm particle size Kinetex 
biphenyl C18 column (Phenomenex Inc, Torrance, CA, USA). Separation conditions 
were: solvent A, water/FA (99.8:0.2); solvent B, MeOH; separation gradient, initially 1% 
B, then linear to 100% B in 4 min, washing with 100% B for 1 min and column 
equilibration with 1% B for 10 min; flow rate, 0.3 mL/min; injection volume, 3 µl; 
autosampler temperature, 6℃; column temperature, 22℃. Mass spectrometry analysis 
was carried out on a Thermo Scientific (Thermo Fisher Sci., Bremen, Germany, EU) Q 
Exactive benchtop Orbitrap detector loading an electrospray (ESI) source operating in 
positive ionization mode. The detector run in Full scan MS analysis under the following 
conditions: spray voltage, 4.0 kV; capillary temperature, 300℃; sheath gas, 55 (arbitrary 
units); auxiliary gas, 30 (arbitrary units); microscans, 1; AGC target, 1e
6
; maximum 
injection time, 100 ms; mass resolution, 70,000; considered m/z range, 145-165. The MS 
device was calibrated through the commercial calibration solution provided by the 
manufacturer to keep mass tolerance below 3 ppm at any time. The LC-MS platform of 
analysis was controlled by a PC loading the software Xcalibur v. 2.2 SP1.48 (Thermo 
Scientific, San Jose, CA, USA). 
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Following LC-MS acquisition, Thermo *.raw files were processed for untargeted 
analysis using two commercially available software packages from Thermo Scientific. 
Thermo SIEVE (v2.2) was used for the tissue culture experiments and Compound 
Discoverer (v2.0) was used for the embryos, both in conjunction with an in-house library 
of approximately 300 compounds. Deuterium incorporation into IMP and hypoxanthine 
was scored by hand in Xcalibur. Customized settings were as follows: maximum RT 
shift, 0.25 minutes; minimum base peak intensity 50,000; mass tolerance, 5 ppm, peak 
integration, ICIS; smoothing, 3 points; adduct formation, ± H. Spectral alignment above 
0.9 was considered acceptable for all data sets. Retention times were used to reduce 
multiple assignments of spectral features and to confirm metabolite assignment. Data was 
normalized by the total spectral area (TSA) of the features that had a reproducibility 
greater than 75% (CV<0.25) in the pooled quality control (QC). When a QC was not 





H NMR spectra were acquired using a Bruker Avance III 500 
MHz with 1.7 mm TCI MicroCryoProbe system (Bruker BioSpin Corp., Billerica, MA) 
equipped with an autosampler at 300 K. The excitation sculpting pulse sequence was 
used to suppress the water resonance signal. NRMLab and MetaboLab were used to 
process the raw data. Metabolite identification and quantification was done using 
Chenomx 8 NMR Suite (Chenomx Inc., Edmonton, Alberta, Canada) referencing the 
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Birmingham Metabolite Library (Ludwig et al.), and the Human Metabolome Databse 
(Wishart et al., 2007). 
4.2.8 Mitochondrial Respiration and Glycolysis Assays 
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
were measured using the Seahorse XFp Flux Analyzer (Seahorse Bioscience–Agilent 
Technologies, Billerica, MA). Cells at a density of 2.10
5
 cells/mL were seeded in 80µL 
DMEM+10%SVF+PSQ on XFp 8-well micro-plates and incubated for 24h at 37°C, 5% 
CO2.  
For mitochondrial function analysis, based on OCR, cells were washed two times 
with XF media freshly supplemented with 2.5mM of Glucose, 2mM of Glutamine, 1mM 
of Pyruvate and adjusted at pH 7.4. Cells were then incubated in that same media for 1h 
at 37°C in a CO2-free incubator. After calibration, the device first measures a baseline 
then levels of OCR and ECAR after sequential addition of different compounds to each 
well: Oligomycin (an ATP coupler, final concentration of 2µM), Carbonyl cyanide-4 
(trifluoromethoxy) phenylhydrazone (FCCP, an uncoupling agent, final concentration of 
1µM), Antimycin A/Rotenone (Complex I and III inhibitors, final concentration of 1µM).  
For the glycolysis assay, based on ECAR, cells were washed and incubated as 
above except that the media lacked glucose. The treatments were as follows: Glucose 
(final concentration of 10mM), Oligomycin (final concentration of 2µM), 2-
deoxyglucose (2-DG, glucose competitive inhibitor, final concentration of 50mM). 
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After each assay, the media was removed from each well and the plates were 
frozen at -80°C overnight. Cells were then lysed by adding 10µl of lysis buffer (10mM 
Tris pH8, 0.1% Triton X-100) in each well. To determine total protein levels, a Bradford 
assay was carried out adding 200 µL of 1X dye Bradford reagent (Bio-Rad #5000205) to 
each well and using a bovine serum albumin (BSA) standard scale (Bio-Rad #5000207). 
Data from each well were normalized by total protein concentration. Assays were 
analyzed using the Seahorse Data Analysis Software (Seahorse Bioscience–Agilent 
Technologies). 
4.2.9 Deuterated Serine Tracer Experiment 
Labeling of MEFs with 2,3,3-D3-L-serine was performed essentially as 
previously described (Pike et al., 2010). Cells were plated onto 10 cm dishes in triplicate 
at a density of 1 x10
6
 cells per dish. Labeling media was identical to the basal MEM used 
for the growth curve experiments (see above) except methionine was at 10 µM. 1 μM 
cyanocobalamin was added as indicated. Cells were grown in the labeling media for a 
total of four days, with fresh media added after two days. Cells were washed with PBS 
and collected by trypsinization. At the time of cell collection, aliquots of the labeling 
media were collected and stored at -70
o
C to be used for metabolite analysis. Cell pellets 
were snap frozen in liquid nitrogen and stored at -70
o
C until the metabolites could be 
extracted using methanol/chloroform as described above. 
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4.2.10 Statistical analysis 
Growth curves and Seahorse experiments were analyzed in Graphpad Prism using 
a mixed model two-way ANOVA for repeated measures, and Bonferroni post-tests were 
used for pairwise comparisons at individual time points. Unpaired t-tests tests were 
calculated in Microsoft Excel. False discovery rate (q) for the metabolite analyes was 
calculated using the method described by Benjamini and Hochberg (1995). Principal 
component analysis (PCA) was performed with Jmp Pro12 (SAS Institute). Pathway 
analysis was performed using MetaboAnalyst (Xia and Wishart, 2011; Xia et al., 2009). 
Data were log transformed and mean centered prior to PCA and pathway analysis. α was 
set to 0.05 for all experiments.  
4.3 RESULTS 
4.3.1 Formate production in isolated mitochondria 
It has been show that isolated mitochondria are capable of producing formate 
from either serine or glycine (Bao et al., 2016; García-Martínez and Appling, 1993; Pike 
et al., 2010). We hypothesized that mitochondria lacking MTHFD1L would be unable to 
produce formate when given serine or glycine as a substrate. Embryos at E14.5-E16.5 
were dissected from dams that had been supplemented with 2500 mg/kg calcium formate. 







 mitochondria showed a reduction in 
formate produced from serine (Figure 4.1A), but surprisingly there was no difference 






C]Glycine concentrations, indicating that serine and glycine 
were not saturating at these conditions. Immunoblots confirmed the absence of any 
detectable MTHFD1L expression (Figure 4.1C). We observed that ALDH1L2 expression 
was increased in Mthfd1l
z/z
 mitochondria (Figure 4.1 C,D). ALDH1L2 has been reported 
to have 10-CHO-THF hydrolase activity in vitro, converting 10-CHO-THF to formate 
and THF (Krupenko et al., 2010; Strickland et al., 2011), and increased expression of 
ALDH1L2 may account for some of the formate production we have observed. 
4.3.2 Embryo metabolites 
In order to try to identify specific metabolic defects associated with loss of 
MTHFD1L that could be contributing to the defects that we have observed and the effects 




 embryos from either  
unsupplemented dams or dams that had been supplemented with 2,500 mg/kg calcium 
formate (n=5 for each group). We conducted a non-targeted metabolomics screen using 
both NMR and MS and identified a total of 98 metabolites in unsupplemented embryos 
and 117 in supplemented embryos.  
4.3.2.1 Unsupplemented 
We first analyzed metabolite data from embryos from unsupplemented dams in 
order to identify defects associated with loss of MTHFD1L. Metabolites from NMR and 
MS were combined and analyzed by PCA (Figure 4.2). There was clear separation of the 
groups, primarily along Component 1. Metabolite differences were also analyzed by t-
test, and p values were corrected for the false discovery rate (Benjamini and Hochberg, 
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1995). We found that 24 of the 98 detected metabolites were significantly altered by loss 
of MTHFD1L (Table 4.1, see Appendix II for full list of metabolites). The 1C 
metabolites serine, glycine, and formate were significantly different. Serine was elevated, 
and glycine and formate were decreased, consistent with decreased utilization of serine 
for formate synthesis. There were also indications of disrupted energy metabolism. 
Lactate was reduced in Mthfd1l
z/z
 embryos, possibly indicating decreased flux through 
glycolysis. To further explore this possibility, we used the lactate:pyruvate ratio to 
estimate the cytoplasmic NAD
+
:NADH ratio using the method described by Krebs 
(Williamson et al., 1967). This method assumes that the conversion of pyruvate + NADH 
to lactate + NAD
+
 is in chemical equilibrium. Assuming a pH of 7.0 and Keq = 1.11 x10
-4
, 
we estimated the NAD
+




 embryos. We found 
that the NAD
+
:NADH ratio in Mthfd1l
z/z
 embryos (116.2 +/- 12.3) was significantly 
higher than Mthfd1l
+/+
 embryos (88.4 +/- 7.1, p = 0.0024), consistent with decreased flux 
through glycolysis (Lim et al., 2010). The tricarboxylic acid (TCA) cycle also appeared 
to be affected. The entry metabolite into the cycle, citrate, was elevated; whereas the 
downstream metabolites fumarate and (Table 4.2) succinate (Appendix II, q = 0.077) 
were both decreased in Mthfd1l
z/z
 embryos. The ATP pool was also disrupted. In 
Mthfd1l
z/z
 embryos, there was a depletion of the low energy AMP and an accumulation of 
high energy ADP and ATP. 
In order to get a picture of the metabolic pathways affected by loss of MTHFD1L 
we performed a pathway analysis using MetaboAnalyst (Xia and Wishart, 2011; Xia et 




embryos (Impact > 0.2, FDR < 0.05, Table 4.2). Consistent with the previously 
mentioned metabolites, perturbations to pathways involving 1C metabolism (Methane 
metabolism and Serine, Glycine, and Threonine metabolism) and energy metabolism 
(Pyruvate metabolism and TCA cycle) were identified. In addition, seven pathways 
involving amino acid metabolism were identified as significantly altered (Table 4.2). 
Leucine, isoleucine, valine, phenylalanine, tyrosine, glycine, and arginine were all 
depleted in Mthfd1l
z/z
 embryos, though not all reached statistical significance after 
correcting for the FDR (Table 4.1, Appendix II). Aspartate, serine, and threonine (q = 
0.085) were elevated in Mthfd1l
z/z
 embryos. 
4.3.2.2 Formate Supplementation 




 embryos from 
calcium formate supplemented dams to see if any of the metabolites that were altered in 
unsupplemented embryos were normalized with formate supplementation. Indeed, of the 
117 detected metabolites only 9 were significantly different, 4 of which matched 
metabolites that were altered in unsupplemented embryos (Table 4.3, see Appendix III 
for full list). Serine remained elevated, and glycine remained depleted (Table 4.3); 
however, formate was no longer significantly different (Appendix III). Taurine 
abundance was reversed; it was elevated in unsupplemented Mthfd1l
z/z
 embryos but is 
lower in supplemented Mthfd1l
z/z
 embryos. AMP remained depleted in Mthfd1l
z/z
 
embryos. Metabolites were analyzed by PCA, and while there was still separation 
between the groups, there appeared to be more overlap along Component 1 (Figure 4.2).  
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We performed a pathway analysis with MetaboAnalyst and looked specifically at 
the pathways that had been identified in unsupplemented embryos. Of the 12 pathways 
that were altered in unsupplemented embryos, 6 were "restored" in supplemented 
embryos and did not significantly differ (Table 4.2). These include both pathways 
involved in energy metabolism (though Pyruvate metabolism was close to significance at 
FDR = 0.057). 
4.3.3 MEF growth curves 
In order to assess any dysfunction in the synthesis of purines and thymidylate, we 





embryos. The basal media, MEM, contained serine as a source of one carbon units, but 
lacked any nucleotides. Cell growth was monitored using the cell viability assay Cell 
Titer Blue and is shown as the fluorescent signal from the resorufin dye. Although null 
MEFs were viable in MEM, WT cells grew significantly better (p < 0.0001) (Figure 4.3 
A). Addition of thymidine alone to the media resulted in only a small improvement in the 
growth of null MEFs as compared to WT (Figure 4.3 B), though WT MEFs still grew 
better (p = 0.0023). The addition of hypoxanthine alone yielded a larger improvement in 
growth, with null MEFs matching or surpassing the growth of WT MEFs at later time 
points (Figure 4.3 C), and the overall genotype effect was no longer significant (p = 
0.13). With the addition of hypoxanthine and thymidine together or formate alone, the 
growth of null MEFs was almost indistinguishable from that of WT (Figure 4.3 D,E; p = 
0.64 and 0.30 respectively). Neither cell line was able to grow when methionine was 
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replaced with homocysteine and vitamin B12 (not shown). The knockdown of 
MTHFD1L in Mthfd1l
z/z
 MEFs was confirmed by genotyping and immunoblotting 
(Figure 4.3 F). 
4.3.4 Deuterated serine labeling 
Despite the fact that mitochondrially derived 1C units are generally the primary 
source of carbon for methionine synthesis from homocysteine (Davis et al., 2004; Pike et 
al., 2010), loss of MTHFD1L did not significantly alter the concentrations of methionine 
or homocysteine in embryos (Appendix II). To further explore this result, I employed a 
tracer experiment utilizing 2,3,3-D3-L-serine (Herbig et al., 2002). This experiment relies 
on the principle that 1C units derived from carbon 3 of serine which are processed in the 
mitochondria before being incorporated into methionine will only contain one deuterium 
atom (D1) due to the dehydrogenase activity of MTHFD2(L). One-carbon units 
incorporated into methionine via SHMT1 in the cytosol will retain both deuterium atoms 
(D2). We found that singly deuterated methionine in Mthfd1lz/z MEFs accounted for 
almost three-fold less of the total methionine pool as compared to Mthfd1l
+/+
 (Table 4.4). 
Mthfd1l
z/z
 MEFs also showed a trend for an increase in doubly deuterated methionine, 
suggesting the cells are compensating for the loss of MTHFD1L by increasing flux of 
cytosolic serine through SHTM1. Similar results have been seen in HEK293 cells, where 
a block in the mitochondrial folate pathway leads to increased incorporation of 1C units 
from serine into dTTP via the cytosolic pathway, though incorporation into methionine 
was not reported (Ducker et al., 2016). Consistent with previously reported values, about 
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98% of labeled methionine in Mthfd1l
+/+
 cells was mitochondrially derived (Davis et al., 
2004; Pike et al., 2010). The proportion of D1 methionine in Mthfd1l
z/z
 cells was lower at 
only 85% (Table 4.4).  
Previous labeling experiments with deuterated serine were carried out using a 
modified αMEM as the labeling medium, which contains 1 μM vitamin B12 (Herbig et 
al., 2002; Pike et al., 2010). B12 is a required cofactor for the function of methionine 
synthase (Loughlin et al., 1964). DMEM does not typically contain additional B12, so we 
repeated the labeling experiment using the same conditions as before but with the 
addition of 1 μM cyanocobalamin. We found that overall the total amount of labeled 
methionine produced was approximately doubled in both cells lines with the addition of 
B12 (Table 4.5). The differences in singly and doubly deuterated methionine were also 
much more pronounced. The methionine pool in Mthfd1l
+/+
 cells contained five times as 
much singly deuterated methionine as the Mthfd1l
z/z
 cells. Conversely, doubly deuterated 
methionine was five-fold higher in Mthfd1l
z/z
 cells than Mthfd1l
+/+
 cells. Singly 
deuterated methionine still made up most of the labeled methionine in Mthfd1l
+/+
 cells 
but only accounted for 27% of labeled methionine in Mthfd1l
z/z
 cells.  
We also looked at deuterium incorporation into hypoxanthine and IMP as an 
indicator of de novo purine synthesis. 1C units derived from serine can be incorporated 
into purines in one of two ways, either as 10-CHO-THF or as glycine formed by SHMT. 
As is the case with methionine, a mitochondrially derived 1C unit from either glycine or 
10-CHO-THF would contain a single deuterium. 10-CHO-THF derived from the 
cytoplasmic pathway would contain two deuterium atoms. Higher order labeling is 
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possible, with IMP or hypoxanthine incorporating a combination of labeled 10-CHO-
THF and glycine, but only singly deuterated species were detected. We found that 
Mthfd1l
+/+
 cells had a much higher proportion of labeled hypoxanthine and IMP than 
Mthfd1l
z/z
 cells (Table 4.6), suggesting that Mthfd1l
+/+
 cells are utilizing de novo purine 
synthesis, while Mthfd1l
z/z
 cells have to rely more on the salvage pathway. It should be 
noted that while we cannot distinguish whether the deuterium label is derived from 10-
CHO-THF or glycine, in either case a singly deuterated species is indicative of synthesis 
in the de novo purine synthesis pathway rather than the salvage pathway.  
Finally, we examined deuterium labeled serine in both cellular extracts and the 
labeling media in which the cells had been grown. The only external source of serine was 
the 2,3,3-D3-L-serine provided in the labeling medium. Serine could also be synthesized 
intracellularly through several routes. Serine could be synthesized from glycine and CH2-
THF by SHMT, which would have the potential to generate serine with 0, 1, 2 or 3 
deuterium atoms depending on the degree of labeling of glycine and CH2-THF. Serine 
could also be derived from protein degradation or synthesized de novo from the 
glycolytic intermediate 3-phosphoglycerate (Snell, 1986). Serine derived from either of 
these sources would most likely not be deuterated. We found that the abundance of singly 





 MEFs (not shown). However, unlabeled serine was more abundant than the 
triply deuterated species in extracts from Mthfd1l
z/z
 MEFs as well as in the labeling media 
(Table 4.7), suggesting that de novo synthesis of serine is increased in these cells. 
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4.3.5 Energy metabolism in Mthfd1l
z/z
 MEFs 
Our metabolic analysis of Mthfd1l
z/z
 embryos suggested that these embryos may 
have impaired energy metabolism. We utilized the Seahorse XFp Flux Analyzer to 
measure mitochondrial respiration via oxygen consumption rate (OCR) and glycolytic 
flux via extracellular acidification rate (ECAR). Mthfd1l
z/z
 MEFs showed similar 
respiratory function to Mthfd1l
+/+
 MEFs (Figure 4.4, p = 0.62). Both cell lines showed 
well coupled mitochondria after addition of rotenone and the maximal respiration rates 
after the addition of FCCP did not significantly differ. In the glycolysis test, Mthfd1l
z/z
 
MEFs showed lower rates of glycolysis (Figure 4.4, p = 0.010). ECAR did not increase in 
either cell line after the addition of oligomycin, indicating little to no glycolytic reserve in 
these cells. ECAR only significantly differed after the glucose injection and prior to the 
2-DG injection, indicating that the difference in ECAR was due to decreased glycolytic 
flux, rather than acidification of the media by some other cellular process. These results 
































Figure 4.1 Formate production in isolated mitochondria. 
14
C formate produced from 
either L-[3-
14
C]Serine (A) or L-[2-
14
C]Glycine (B) in isolated mitochondria. 
(C) Representative immunoblot of MTHFD1L and ALDH1L2 expression in 
mitochondria isolated from E15.5 and E16.5 embryos. (D) Densitometry of 













































































































Figure 4.2 Principal component analysis of embryo metabolites. PCA plots were 
generated for metabolites from embryos from unsupplemented (top) and 
































Figure 4.3  MTHFD1L null MEF growth curves. Cell growth was monitored using the 
cell viability assay CellTiter Blue. (A-E) Cells were grow in basal MEM 
(described in "Materials and Methods") with additional 30 μM thymidine 
(T), 30 μM hypoxanthine (H), or 1 mM formate (F) as indicated. (F) 
Knockdown of MTHFD1L expression was confirmed by genotyping and 
immunoblotting. * = p < 0.05, ** = p < 0.001, *** = p < 0.0001 as 































Figure 4.4  Energy metabolism in Mthfd1l
z/z
 MEFs. Mitochondrial respiration (top) and 
glycolysis (bottom) were analyzed in MEFs using the Seahorse XFp Flux 
Analyzer as described in "Materials and Methods." Data points represent the 
mean rates of triplicate determinations +/- SD. Dashed lines represent 
injections of the indicated compounds. * p < 0.01, ** p < 0.0001 as 































































 q value 
Taurine 1.07 0.0089 
Fumarate 0.84 0.0067 
Arginine 0.86 0.0052 
Glycine 0.85 0.013 
Lactate 0.82 0.012 
ADP 1.26 0.013 
Serine 1.16 0.013 
Glutathione 1.05 0.017 
Leucine 0.87 0.017 
ATP 1.33 0.016 
Fucose 1-phosphate* 1.27 0.016 
Creatine 1.09 0.020 
5-Hydroxymethyl-2-furanoate* 1.29 0.020 
Isoleucine 0.81 0.021 
AMP 0.76 0.023 
Valine 0.88 0.029 
Formate 0.93 0.028 
Citrate 1.28 0.027 
Uracil 0.82 0.026 
Acetate 0.90 0.030 
Phosphocholine 1.11 0.032 
Ascorbic acid* 1.26 0.039 
Phosphoethanolamine 1.15 0.044 
Aspartate 1.28 0.044 
Table 4.1 Significantly altered metabolites in Mthfd1l
z/z
 embryos. The ratio of the 
abundance of the given metabolite in Mthfd1l
z/z
 embryos relative to the 
abundance in Mthfd1l
+/+
 embryos is shown. False discovery rate (q value) 
was calculated from p values using the method described by Benjamini and 
Hochberg (Benjamini and Hochberg, 1995). * indicates metabolites detected 












 9 3 2.76E-06 5.32E-06 
Citrate cycle (TCA cycle)
c
 20 6 0.0028 0.52 
Alanine, aspartate and glutamate 
metabolism
b
 24 8 0.0054 0.027 
Arginine and proline 
metabolism
b
 44 10 0.0057 0.13 
Glyoxylate and dicarboxylate 
metabolism 18 4 0.0057 0.39 
Valine, leucine and isoleucine 
biosynthesis
b
 11 4 0.0057 0.63 
Pyruvate metabolism
c
 23 4 0.0063 0.057 
Glycine, serine and threonine 
metabolism
ab
 31 7 0.012 5.32E-06 
Histidine metabolism
b
 15 2 0.018 0.020 
Phenylalanine metabolism
b
 11 2 0.026 0.023 
Phenylalanine, tyrosine and 
tryptophan biosynthesis
b
 4 2 0.026 0.023 
beta-Alanine metabolism 17 4 0.028 0.13 
 
Table 4.2 Pathway analysis by MetaboAnalyst. Metabolic pathways that were found to 
be significantly altered (based on FDR) in Mthfd1l
z/z
 embryos from 
unsupplemented dams. The rightmost column shows how each pathway has 





). Pathways involved in 1C (a), amino acid (b), and 
energy metabolism (c) were identified. Red text indicates pathways that 







 q value 
Serine 3.06 1.33E-06 
Glycine 0.59 0.0029 
Diethyl fumarate* 1.89 0.0051 
Asparagine 1.32 0.0074 
Taurine 0.84 0.011 
3-Methyladipic acid/Ethyl methyl succinate* 1.19 0.026 
Histidine 1.35 0.049 
AMP 0.57 0.043 
Glycerophosphocholine 0.72 0.045 
 
Table 4.3 Significantly altered metabolites in Mthfd1l
z/z
 embryos from calcium 
formate supplemented dams. The ratio of the abundance of the given 
metabolite in supplemented Mthfd1l
z/z
 embryos relative to the abundance in 
supplemented Mthfd1l
+/+
 embryos is shown. False discovery rate (q value) 
was calculated from p values using the method described by Benjamini and 
Hochberg (Benjamini and Hochberg, 1995). * indicates metabolites detected 
by LC-MS; all others were detected by NMR. 
  
 107 
 Fraction of Total (M+D1+D2) Fraction of Labeled 
(D1+D2) 



























p value 0.0006 0.1051 0.0007 0.0501 0.0501 
Table 4.4 Methionine labeling with deuterated serine. MEFs were plated in triplicate 
in 10 cm dishes at a density of 1 x 10
6
 cells per dish and were grown in 
labeling media for four days as described in "Materials and Methods." 
Incorporation of the deuterium label into methionine was measured by LC-
MS. Means of triplicate determinations +/- SD are shown. M = unlabeled 
methionine, D1 = methionine + 1 deuterium, D2 = methionine + 2 




Fraction of Total (M+D1+D2) 
Fraction of Labeled 
(D1+D2) 
 



























p value 6.70E-06 0.0011 5.80E-04 5.60E-05 6.00E-05 
 
Table 4.5 Methionine labeling with deuterated serine and B12. MEFs were plated in 
triplicate in 10 cm dishes at a density of 1 x 10
6
 cells per dish and were 
grown in labeling media for four days as described in "Materials and 
Methods." Incorporation of the deuterium label into methionine was 
measured by LC-MS. Means of triplicate determinations +/- SD are shown. 
M = unlabeled methionine, D1 = methionine + 1 deuteron, D2 = methionine 




Fraction of Total (IMP + 
IMP+D) 
Fraction of Total (Hyp + 
Hyp+D) 
 
IMP IMP+D Hyp Hyp+D 
MTHFD1L
+/+
 0.18 +/- 0.02 0.82 +/- 0.02 0.22 +/- 0.01 0.78 +/- 0.01 
MTHFD1L
-/-
 0.90 +/- 0.009 0.1 +/- 0.009 0.81 +/- 0.03 0.19 +/- 0.03 
p value 5.87E-06 5.87E-06 0.00024 0.00024 
 
Table 4.6 Purine labeling with deuterated serine and B12. MEFs were plated in 
triplicate in 10 cm dishes at a density of 1 x 10
6
 cells per dish and were 
grown in labeling media for four days as described in "Materials and 
Methods." Incorporation of the deuterium label into IMP and hypoxanthine 
(Hyp) was measured by LC-MS. Means of triplicate determinations +/- SD 
are shown. IMP+D = IMP + 1 deuteron, Hyp+D = Hyp + 1 deuteron. P 





Fraction of total serine  
(S + D1 + D2 + D3) 
Intracellular S D3 
Mthfd1l
+/+
 0.25 +/- 0.02 0.41 +/- 0.04 
Mthfd1l
z/z
 0.34 +/- 0.03 0.31 +/- 0.01 
p value 0.012 0.012 
Media S D3 
Mthfd1l
+/+
 0.12 +/- 0.04 0.88 +/- 0.04 
Mthfd1l
z/z
 0.34 +/- 0.07 0.66 +/- 0.07 
p value 0.0087 0.0087 
Table 4.7  De novo serine synthesis in Mthfd1l
z/z
 MEFs. MEFs were plated in triplicate 
in 10 cm dishes at a density of 1 x 10
6
 cells per dish and were grown in 
labeling media for four days as described in "Materials and Methods." 
Deuterium labeling of serine from cellular extracts and serine effluxed into 
the media was measured by LC-MS. Means of triplicate determinations +/- 
SD are shown. S = unlabeled serine, D1 = serine + 1 deuteron, D2 = serine + 






We had hypothesized that isolated, intact mitochondria from Mthfd1l
z/z
 embryos 
would produce minimal formate from glycine or serine. We found that labeled formate 
production from Mthfd1l
z/z
 mitochondria using L-[3-
14
C]Serine as a substrate was 
reduced, but some formate was still being formed. This suggests some alternate means of 
making formate from the 3-carbon of serine exists in the mitochondria. One possibility is 
that cytoplasmic MTHFD1 and SHMT1 are being copurified on the outside of the 
mitochondria. This is unlikely to account for the activity, however, as the concentrations 
of the necessary cofactors NADP
+
, THF, and ADP outside the mitochondria are likely 
too low allow for any copurified proteins to be catalytically active. This is supported by a 
study from our lab in which extracts from sonicated mitochondria were given L-[3-
14
C]Serine and formation of labeled formate was measured. Production of formate was 
only detected when the appropriate cofactors were added back to the system (García-
Martínez and Appling, 1993). Another possibility is that formate is being produced from 
10-CHO-THF by the hydrolase activity of ALDH1L2 (Krupenko et al., 2010; Strickland 
et al., 2011). Although 10-CHO-THF hydrolase activity in ALDH1L2 has only been 
demonstrated in vitro, if it occurs in vivo, it could account for the ability of Mthfd1l
z/z
 
mitochondria to produce formate from L-[3-
14
C]Serine. We observed that expression of 
ALDH1L2 was increased in Mthfd1l
z/z
 embryos. This increase in expression is likely the 
cell compensating for the bottleneck at 10-CHO-THF caused by loss of MTHFD1L, but 
whether that compensation is simply to regenerate THF by releasing the 1C unit as CO2 
or to provide supplementary formate production has yet to be determined. Work is 
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C]Glycine as a substrate, formate production in Mthfd1l
z/z
 
mitochondria was indistinguishable from that of Mthfd1l
+/+
 mitochondria. This was a 
surprising result and likely indicates that at least some of the formate produced from 
glycine is obtained via a different route from that of serine. If the only pathway for 
production of formate from glycine was through the folate-dependent pathway involving 
GCS and the intermediate 10-CHO-THF, we could reasonably expect to see a similar 
reduction in formate production that is seen with serine. There is evidence for a folate 
independent pathway that can produce formate from glycine via a glyoxylate 
intermediate (Nakada et al., 1955). There are several potential routes for formation of 
glyoxylate from glycine. The most likely route seems to be through D-amino acid 
oxidase, which is typically a peroxisomal protein but has also been found to localize with 
the mitochondria (Sacchi et al., 2011). D-amino acid oxidase catalyzes the deamination 
of glycine to form glyoxylate (de Marchi and Johnston, 1969). There is also evidence for 
nonenzymatic transamination reactions under physiological conditions between 
glyoxylate and several different amino acids to form glycine, though it was not shown 
whether or not these reactions would proceed in the direction of glycine catabolism 
(Nakada and Weinhouse, 1953). Another possibility is the mitochondrial 
alanine:glyoxylate aminotransferase (AGT2) which catalyzes a transamination between 
alanine and glyoxylate to form pyruvate and glycine. However, this reaction has been 
reported to proceed exclusively in the direction of glycine synthesis in vitro, so it is 
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unlikely that AGT2 would contribute to glyoxylate synthesis in mitochondria (Noguchi et 
al., 1978; Thompson and Richardson, 1967). Once glyoxylate is formed, it is oxidized to 
CO2 and formate (Nakada et al., 1955). This oxidation can occur either enzymatically or 
nonenzymatically. After a search of the existing literature, the enzymatic pathway of 
glyoxylate oxidation does not appear to be fully described, but is has been shown to 
require NAD
+
, does not require folate (Nakada and Sund, 1958), and appears to involve a 
condensation with α-ketoglutarate (Kawasaki et al., 1966). Alternatively, glyoxylate can 
react non-enzymatically with H2O2 to form CO2 and formate (Kenten and Mann, 1952).  
Even though Mthfd1l
z/z
 mitochondria retain some formate production capacity, it 
is apparently insufficient to support proper embryonic development, since formate 
supplementation of the dams partially rescues the NTD and growth defects (Momb et al., 
2013). It's possible that the flux of formate from the mitochondria is simply too low to 
supply cellular 1C needs. This is supported by the decrease in formate in Mthfd1l
z/z
 
embryos and a lower abundance of labeled methionine in Mthfd1l
z/z
 MEFs. An alternate 
possibility is that there exists a mechanism of channeling formate made by MTHFD1L in 
the mitochondria into MTHFD1 in the cytoplasm. The total cellular formate 
concentration could remain relatively low, but formate would still be available for 
synthetic reactions in the cytoplasm. Mitochondrial formate produced either by 
ALDH1L2 or via glyoxylate would not be channeled to MTHFD1, and cellular formate 
would remain too dilute to supply cellular synthetic requirements. 
The etiology of NTDs in Mthfd1l
z/z
 embryos is likely influenced by numerous 
factors, making it difficult to identify any one factor that is causing the NTDs. 
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Nevertheless, we identified a variety of metabolic defects associated with loss of 
MTHFD1L that are likely contributing to the abnormal neural tube closure and growth 
delay seen in Mthfd1l
z/z
 embryos. In a stable isotope tracer experiment with deuterated 
serine we identified disruptions to methionine synthesis which could have downstream 
effects on the methyl cycle. We also observed an apparent decrease in de novo purine 
synthesis in Mthfd1l
z/z
 MEFs. Using growth curves we found that the growth of Mthfd1l
z/z
 
MEFs could be rescued with supplementation of nucleotide precursors. Proper function 
of both the methyl cycle and nucleotide synthesis are essential for development. 
Inhibiting SAM synthesis from methionine and inhibiting DNA methylation both cause 
NTDs in mice (Dunlevy et al., 2006; Matsuda, 1990). Inhibition of de novo purine 
synthesis with lometrexol induces NTDs in 30% of mouse embryos (Xu et al., 2016), and 
defects in purine synthesis have been found in a mouse model of NTDs (Hansler et al., 
2014). Disruption of thymidylate synthesis by knocking out SHMT1 is also associated 
with NTDs (Beaudin et al., 2011). Finally, disruptions to both purine and thymidylate 
synthesis are associated with valproate-induced NTDs in mice (Akimova et al., 2016). 
Using a non-targeted metabolomics screen and pathway analysis with 
MetaboAnalyst, we also identified disruptions to the metabolism of multiple amino acids 
as well as energy metabolism. Many of the affected amino acids were depleted in 
Mthfd1l
z/z
 embryos, which could have negative effects on protein synthesis required for 
rapid cell growth and division during neural tube closure. The disruption of so many 
amino acids beyond the 1C metabolites glycine and serine is interesting and warrants 
further study. Metabolites involved in both glycolysis and the TCA cycle were also 
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affected. Though we did not detect any differences in mitochondrial respiration in 
Mthfd1l
z/z
 MEFs, we did observe significantly decreased flux through glycolysis 
compared to Mthfd1l
+/+
 MEFs. Disruptions to glycolysis have also been implicated in 
NTDs. Cultured embryos treated with 100 μM 2-DG develop NTDs with 100% 
penetrance (Hunter and Tugman, 1995).  
Formate supplementation appeared to normalize many of the metabolites that 
were perturbed by loss of MTHFD1L. All of the TCA cycle intermediates that were 
disrupted in unsupplemented Mthfd1l
z/z
 embryos appeared to be rescued by formate 
supplementation. In addition, calculation of the NAD
+
:NADH ratio in supplemented 
embryos revealed that this ratio was no longer significantly different (not shown), 
suggesting that the defect in glycolysis had also been normalized. Prior to these results, 
we did not anticipate the effect the loss of MTHFD1L would have on glycolysis and the 
TCA cycle, and the role formate supplementation has in rescuing these pathways is still 
unclear. Within the last few years, folate-dependent 1C metabolism has emerged as an 
important source of energy production in certain types of cancer. Serine derived from the 
glycolytic intermediate 3-phosphoglycerate is broken down to generate ATP and NADPH 
(Tedeschi et al., 2013), though it is unclear if this process is relevant to embryogenesis. 
More work will be needed to elucidate the connection between 1C metabolism and 
energy metabolism in developing embryos. 
Though we hypothesized formate would provide a source of 1C units for the 
synthesis of purines, thymidylate, and methionine, there were no clear indications from 




 embryos showed that formate supplementation rescued growth to 
a similar degree as hypoxanthine and thymidine, suggesting that formate and the 
nucleotide precursors may be affecting similar pathways, but this result is not conclusive. 
Experiments with cultured embryos have shown that formate supplementation decreases 
uptake of exogenous adenine and thymidine (Sudiwala et al., 2016), substantiating the 
idea that formate supports nucleotide synthesis. Future tracer experiments using 
13
C 
formate will likely be needed to confirm specific metabolites that are being generated 
from the 1C units provided by formate. 
The results reported here suggest some potential alternative supplements to 
prevent NTDs in Mthfd1l
z/z
 mice. A combination of hypoxanthine and thymidine was 
successful in rescuing the growth of Mthfd1l
z/z
 MEFs. This could be advantageous over 
formate supplementation, because a large amount of formate is necessary to rescue NTDs 
in Mthfd1l
z/z
 embryos (Figure 4.1), and formate can be toxic to embryos at high 
concentrations (Andrews et al., 1995). In the growth curve experiments however, a 
comparatively small amount of nucleotides was able to achieve the same result as a much 
larger amount of formate (30 μM nucleotides vs. 1 mM formate, Figure 4.4). If this result 
holds true for Mthfd1l
z/z
 embryos, nucleotide precursors may be able to prevent NTDs 
with a lower risk of adverse effects. Successful rescue of NTDs with nucleotides has been 
reported previously. Supplementation with a combination of thymidine and adenine has 
been shown to reduce spina bifida by 85% in curly tail mice (Leung et al., 2013). 
Supplementation with the TCA cycle intermediates succinate or fumarate, which were 
depleted in Mthfd1l
z/z
 embryos but rescued with formate supplementation, may also be 
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worth pursuing. More work will be needed to test these compounds and identify new 
supplements that are effective in preventing folic acid resistant NTDs.  
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Chapter 5: Summary and Future Directions 
In the preceding chapters, studies centered on the mitochondrial folate-dependent 
enzymes MTHFD1L and MTHFD1L have been described. For decades the only known 
mitochondrial CH2-THF dehydrogenase/CH
+
-THF cyclohydrolase was MTHFD2 (Mejia 
and MacKenzie, 1985; Mejia et al., 1986). This protein could only be detected in 
immortalized mammalian cells, embryos, or nondifferentiated tissues, but not in adult 
differentiated tissues (Christensen and Mackenzie, 2008). MTHFD2L, which was first 
described by our laboratory (Bolusani et al., 2011), accounts for the CH2-THF 
dehydrogenase/CH
+
-THF cyclohydrolase activity that had previously been detected in 
adult liver mitochondria (Barlowe and Appling, 1988). Though it is still unknown why 
mammals possess two mitochondrial CH2-THF dehydrogenases, we have identified 
differences in the expression of these isozymes and details of alternative splicing of 
MTHFD2L that may help shed some light on this question. We identified an apparent 
regulatory switch between E8.5 and E10.5 where expression of MTHFD2L increases and 
remains high throughout development. MTHFD2 expression was low at all time points 
examined, but higher expression has been reported at earlier embryonic days (Pike et al., 
2010). In adults, MTHFD2L was widely expressed, with highest expression in brain and 
lung. Expression of MTHFD2 was low in most tissues, but modest expression was 
detected in the proliferative tissues testis and spleen. Future work identifying 
transcriptional regulators of MTHFD2L and MTHFD2 will help to better explain the 
temporal and spatial differences in their expression. The abundant splice variant of 
MTHFD2L lacking exon 8 was not found to be catalytically active, but future work could 
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identify a structural role for this splice variant similar to the structural role that has been 
reported for MTHFD2 in the nucleus (Gustafsson Sheppard et al., 2015). 
In adult mice, we identified several behavioral anomalies associated with loss of 
MTHFD1L and folate deficiency, but more work will be needed to further investigate 
these findings. There were indications of a hyperactive phenotype in male mice 
associated with the mutant genotype. Female mice showed a diet-dependent aversion to 
the margin in open field and increased freezing during tone-shock training in a fear 
conditioning experiment, suggesting increased anxiety. This study was limited by 
inconsistent knockdown of MTHFD1L, particularly in the folate deficient mice. Several 
strategies may improve future studies. Tamoxifen treatment of mice by gavage rather 
than in the diet will give a more consistent Tamoxifen exposure. Using mice that are null 
for MTHFD1L in one allele and have the conditional cassette in the other allele may 
result in a more efficient knockdown. Aging the mice longer could give time for age-
related deficits to become apparent. Finally, more stringent behavioral tests such as trace 
fear conditioning or the Morris water maze could reveal subtle defects that could not be 
detected in this study. 
Finally we examined the metabolic consequences of deleting MTHFD1L in 
mouse embryos. We found that while deletion of MTHFD1L reduces mitochondrial 
production of formate from serine in isolated mitochondria, some formate synthesis 
capacity remains. This redundancy may be in part explained by an increase in the 
expression of ALDH1L2, which has been shown to have 10-CHO-THF hydrolase activity 
in vitro (Krupenko et al., 2010; Strickland et al., 2011). Work is currently underway to 
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generate mice that are nullizygous for both MTHFD1L and ALDH1L2. If ALDH1L2 
alone is responsible for the redundant formate synthesis in Mthfd1l
z/z
 embryos, 
mitochondria isolated from MTHFD1L/ALDH1L2 nullizygous embryos will completely 
unable to oxidize serine to formate.  
Using several different methods we identified a range of metabolic defects in 
Mthfd1l
z/z
 embryos that could contribute to the NTDs and growth restriction we have 
previously reported (Momb et al., 2013). We identified alterations in the TCA cycle, 
glycolysis, the metabolism of multiple amino acids, and the synthesis of methionine and 
purines. It is possible that supporting one or more of these affected pathways with 
supplementation of the appropriate nutrient may help to alleviate the defects observed in 
Mthfd1l
z/z
 embryos. Future work testing the efficacy of different supplements could 









AD Alzheimer's disease 
AGT2 alanine:glyoxylate aminotransferase 
ALDH aldehyde dehydrogenase 
AMT aminomethyltransferase 






CHO Chinese hamster ovary  
CS conditioning stimulus 
DHF dihydrofolate 
DHFR dihydrofolate reductase 
DMEM Dulbecco's modified Eagle's medium 
DMG dimethylglycine 
ECAR extracellular acidification rate 
eEF2 eukaryotic elongation factor 2 
FBS fetal bovine serum 
FCCP carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone 
FD folate-deficient diet 
Folr Folate receptor protein 
FPGS folylpolyglutamate synthetase  
GCS glycine cleavage system 
GCSH GCS H-protein 
GCSL GCS dihydrolipoyl dehydrogenase 
GLDC glycine decarboxylase 
GRHL3 grainyhead-like 3 
Hcy homocysteine 
HRP horseradish peroxidase 
IMP inosine monophosphate 
LOAD late onset Alzheimer's disease 
MEF mouse embryonic fibroblast 
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MEM modified Eagle's medium 
MFT mitochondrial folate transporter 
MHP median hinge point 
MTFMT methionyl-tRNA formyltransferase 
MTHFD1 methylene-tetrahydrofolate 1 
MTHFD1L methylene-tetrahydrofolate 1-like 
MTHFD2 methylene-tetrahydrofolate 2 
MTHFD2L methylene-tetrahydrofolate 2-like 
MTHFR methylenetetrahydrofolate reductase 
NAD
+
 nicotinamide adenine dinucleotide 
NADP
+
 nicotinamide adenine dinucleotide phosphate 
NCC neural crest cell 
NTD neural tube defect 
OCR oxygen consumption rate 
PABA para-aminobenzoic acid 
PAGE polyacrylamide gel electrophoresis 
PCA principal component analysis 
PCFT proton coupled folate transporter 
PCR polymerase chain reaction 
RFC reduced folate carrier 
RT-PCR real-time polymerase chain reaction 
SAH S-adenosylhomocysteine 
SAM S-adenosylmethionine 
SD standard deviation 
SDS sodium dodecyl sulfate 
SEM standard error of the mean 
SHMT serine hydroxymethyltransferase 
TBP TATA-box-binding protein 
TCA tricarboxylic acid cycle 
THF tetrahydrofolate 
























(3-Aminopropoxy)guanidine 1.07 0.57 15.2% 11.6% 
1-Methyl-3-(2-thiazolyl)-1H-indole 0.71 0.08 19.9% 16.0% 
2-Amino-3-phosphonopropionic acid 1.20 0.09 10.4% 11.1% 
2-Hydroxy-4-(methylthio)butanoic 
acid 1.31 0.09 21.8% 11.3% 
2-Hydroxyadipic acid/3-
Hydroxyadipic acid 1.01 0.94 12.5% 8.0% 
5-Hydroxyindoleacetic acid 0.79 0.16 23.4% 11.8% 
5-Hydroxymethyl-2-furanoate 1.29 0.02 10.9% 8.3% 
Acetate 0.90 0.03 3.8% 5.6% 
ADP 1.26 0.01 8.0% 6.1% 
Alanine 1.02 0.49 2.6% 3.7% 
Allantoin 1.01 0.94 20.1% 15.4% 
Aminoadipic acid 1.09 0.46 12.9% 15.5% 
AMP 0.76 0.02 10.7% 9.2% 
Arginine 0.86 0.01 4.0% 2.9% 
Ascorbic acid 1.26 0.04 13.5% 8.1% 
Asparagine 1.00 0.93 5.6% 3.7% 
Aspartate 1.28 0.04 11.9% 11.7% 
ATP 1.33 0.02 12.3% 7.4% 
b-Alanine 1.02 0.88 16.2% 11.9% 
Carnitine 1.07 0.61 16.6% 11.9% 
Choline 0.88 0.12 8.6% 10.3% 
cis-Aconitic acid/trans-Aconitic acid 1.12 0.35 16.1% 12.7% 
Citrate 1.28 0.03 10.2% 10.0% 
Citrulline 1.24 0.17 21.8% 14.2% 
Creatine 1.09 0.02 3.2% 2.7% 
Cytidine 0.84 0.23 18.5% 13.4% 
D-Glucose 1.24 0.08 7.9% 14.7% 
Diethyl fumarate 1.04 0.65 9.0% 11.9% 
Dihydrothymine 0.81 0.25 25.6% 10.3% 
Erythronic acid 1.14 0.40 8.9% 23.2% 
Formate 0.93 0.03 3.2% 3.1% 
Fucose 1-phosphate 1.27 0.02 7.3% 8.6% 
Fumarate 0.84 0.01 3.7% 4.3% 




Alanine/beta-Alanyl-L-lysine 1.08 0.58 11.0% 18.2% 
gamma-L-Glutamyl-L-methionine 
sulfoxide 1.15 0.29 15.8% 15.7% 
Glutamate 1.07 0.11 4.6% 5.0% 
Glutamine 0.80 0.12 19.2% 6.5% 
Glutarylglycine/N-Acetylglutamic 
acid 1.29 0.10 20.8% 13.4% 
Glutathione 1.05 0.02 1.5% 1.8% 
Glycerophosphocholine 1.11 0.12 7.7% 6.9% 
Glycine 0.85 0.01 5.4% 2.9% 
Glycyl-Phenylalanine/Phenylalanyl-
Glycine 1.01 0.95 20.8% 7.4% 
Glycylproline 1.01 0.64 4.3% 2.4% 
Guanine 0.91 0.32 12.4% 9.0% 
Histidine 0.90 0.12 5.3% 9.2% 
Homocysteinesulfinic acid 1.10 0.31 14.4% 7.5% 
Homo-L-arginine 1.02 0.90 10.6% 20.4% 
Hydroxyglutaric acid 1.17 0.45 15.6% 28.6% 
Hypotaurine 1.17 0.13 15.6% 6.7% 
Inosine 1.08 0.61 20.0% 14.2% 
Isocitric acid 1.13 0.27 13.1% 13.3% 
Isoleucine 0.81 0.02 8.1% 7.0% 
Kynurenine 0.92 0.62 21.3% 17.9% 
Lactate 0.82 0.01 3.8% 7.9% 
Leucine 0.87 0.02 4.9% 4.3% 
L-Homocysteic acid 1.23 0.19 23.1% 14.3% 
L-Threonine 1.47 0.08 18.5% 23.4% 
Lysine 0.95 0.15 2.3% 5.0% 
Maleic acid 1.11 0.34 13.6% 11.3% 
Malic acid 1.11 0.25 11.4% 9.3% 
Methionine 1.06 0.45 10.6% 6.4% 
Mono-trans-p-coumaroylmesotartaric 
acid 1.03 0.88 22.7% 14.3% 
Myo-Inositol 1.08 0.08 3.2% 5.7% 
N-Acetylaspartylglutamic acid 1.25 0.11 15.6% 14.7% 
N-Acetyl-L-aspartic acid 1.22 0.11 14.8% 12.4% 
N-Acetyl-L-aspartic acid/N-Formyl-L-
glutamic acid/D-N-
(Carboxyacetyl)alanine/2-Amino-3- 1.24 0.09 17.2% 10.0% 
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oxoadipate 
N-Acetyl-L-methionine 1.07 0.62 14.1% 15.3% 
NAD 1.83 0.13 62.8% 34.1% 
Niacinamide 0.90 0.30 8.5% 16.2% 
Ornithine 0.91 0.11 6.4% 5.8% 
Pantothenate 0.80 0.07 7.2% 16.4% 
Phenylalanine 0.91 0.08 6.3% 4.6% 
Phosphocholine 1.11 0.03 6.0% 3.2% 
Phosphodimethylethanolamine 1.03 0.72 7.1% 12.0% 
Phosphoethanolamine 1.15 0.04 8.1% 5.3% 
Phosphoric acid 0.95 0.13 3.6% 3.5% 
Proline 0.99 0.74 5.1% 1.7% 
Pyroglutamic acid 0.99 0.85 5.8% 5.4% 
Pyruvate 1.07 0.15 7.0% 3.4% 
Ribitol 1.26 0.08 15.1% 12.5% 
Sarcosine 1.04 0.78 10.6% 16.7% 
S-Carboxymethyl-L-cysteine 1.10 0.44 13.3% 15.3% 
Serine 1.16 0.01 4.3% 4.8% 
Spermine 1.20 0.27 26.9% 10.1% 
Succinic acid 0.76 0.08 18.2% 7.9% 
Taurine 1.07 0.01 1.7% 1.1% 
Theanine 1.02 0.92 6.3% 26.9% 
Threonic acid 1.24 0.13 19.1% 13.0% 
Tryptophan 1.03 0.71 7.6% 10.8% 
Tyrosine 0.92 0.10 6.4% 3.3% 
UDP-Acetylgalactosamine 1.01 0.94 16.9% 16.6% 
UDP-Acetylglucosamine 1.09 0.06 3.8% 4.6% 
UMP 0.85 0.09 11.5% 7.6% 
Uracil 0.82 0.03 7.3% 9.8% 
Urea 0.84 0.08 9.5% 10.4% 
Uridine 0.71 0.08 22.1% 12.0% 
Valine 0.88 0.03 5.9% 4.0% 
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(3-Aminopropoxy)guanidine 0.89 0.24 9.3% 13.6% 
1-Pyrroline-5-carboxylic acid 0.91 0.55 18.5% 16.0% 
2-Hydroxy-4-(methylthio)butanoic 
acid 1.86 0.21 50.9% 41.3% 
2-Hydroxyadipic acid 0.90 0.34 6.8% 18.6% 
2-Hydroxyglutaric acid 0.88 0.28 9.2% 17.3% 
2-Keto-glutaramic acid 0.87 0.19 5.7% 13.2% 
2-Oxoglutaric acid/3-Oxoglutaric acid 1.33 0.10 10.0% 16.9% 
3-Methyladipic acid/Ethyl 
methyl_succinate 1.19 0.03 6.8% 4.8% 
4-Hydroxy-2-oxoglutarate 0.92 0.61 19.9% 15.8% 
4-Hydroxycitrulline 1.09 0.41 10.8% 13.1% 
4-Hydroxyproline 1.74 0.19 42.3% 39.0% 
4-Phosphopantothenoylcysteine 1.52 0.18 27.3% 34.3% 
5-Aminoimidazole 1.03 0.87 25.2% 13.8% 
Acetate 1.24 0.10 15.3% 6.3% 
Acetylcarnitine 1.45 0.18 22.6% 32.6% 
ADP 1.17 0.43 34.6% 7.3% 
Alanine 1.06 0.18 5.0% 4.3% 
Alanyl-Aspartate/Aspartyl-Alanine 1.14 0.19 8.8% 10.6% 
Allantoin 1.01 0.90 12.1% 10.9% 
Aminoadipic acid/Acetylhomoserine 0.89 0.26 8.2% 15.2% 
AMP 0.57 0.04 22.0% 12.2% 
Arginine 0.83 0.17 14.9% 6.6% 
Ascorbic acid 0.84 0.19 13.3% 11.2% 
Asparagine 1.32 0.01 9.0% 5.4% 
Aspartate 0.85 0.18 17.1% 3.5% 
Aspartyl-Cysteine/Cysteinyl-Aspartate 1.88 0.21 52.0% 41.6% 
ATP 1.47 0.13 34.6% 12.9% 
b-Alanine 1.19 0.14 8.8% 12.0% 
Choline 0.94 0.39 9.0% 9.3% 
Citrate 0.88 0.18 14.3% 3.2% 
Citrulline 0.87 0.26 12.0% 16.0% 
Creatine 0.89 0.18 9.9% 3.9% 
Cytidine 1.46 0.07 27.0% 6.9% 
Diethyl fumarate 1.89 0.01 18.7% 11.7% 
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Dimethyl succinate 1.25 0.11 11.7% 12.5% 
Formate 1.10 0.19 6.0% 6.8% 
Fucose 1-phosphate 1.79 0.20 46.2% 40.1% 
Fumarate 1.04 0.78 17.9% 13.7% 
Galactonic acid/Gulonic acid 1.09 0.24 7.5% 9.8% 
gamma-L-Glutamyl-L-methionine 
sulfoxide 1.14 0.07 6.9% 5.0% 
Glucose 0.96 0.75 8.2% 14.9% 
Glutamate 1.01 0.87 6.6% 2.2% 
Glutamine 1.02 0.80 9.7% 4.0% 
Glutamylalanine 0.84 0.09 8.1% 8.9% 
Glutarylglycine/N-Acetylglutamic 
acid 0.86 0.20 10.2% 15.8% 
Glutathione 0.91 0.19 7.1% 7.3% 
Glycerol 3-phosphate 0.91 0.47 20.0% 6.0% 
Glycerophosphocholine 0.72 0.04 14.9% 4.4% 
Glycerylphosphorylethanolamine 1.30 0.22 13.2% 28.7% 
Glycine 0.59 0.00 11.1% 5.2% 
Glycyl-Phenylalanine/Phenylalanyl-
Glycine 1.05 0.70 16.1% 12.6% 
Glycylproline 0.85 0.15 12.7% 6.5% 
Histidine 1.35 0.05 17.7% 3.5% 
Homocysteic acid 1.03 0.67 10.5% 5.9% 
Homocysteinesulfinic acid 0.94 0.27 6.8% 5.3% 
Homo-L-arginine 0.97 0.80 18.0% 16.2% 
Hydantoin-5-propionic acid 1.14 0.19 11.1% 9.8% 
Hydroxyglutaric acid 1.57 0.18 30.8% 35.5% 
Hydroxyprolyl-Valine/Valyl-
Hydroxyproline 1.66 0.19 37.3% 37.6% 
Hypotaurine 0.95 0.56 9.8% 9.1% 
Iminoaspartic acid/2-Oxosuccinamate 1.29 0.23 12.1% 28.2% 
Isocitric acid 0.99 0.91 18.2% 17.4% 
Isoleucine 0.94 0.66 18.7% 6.0% 
Itaconic acid 0.86 0.20 13.1% 12.6% 
Kynurenine 1.70 0.19 39.5% 38.2% 
Lactate 1.03 0.73 13.1% 3.3% 
L-beta-aspartyl-L-glycine/Carglumic 
acid/Aspartyl-Glycine/Glycyl-
Aspartate 1.62 0.19 34.1% 36.6% 
L-Carnitine 0.96 0.77 16.3% 15.8% 
Leucine 0.98 0.82 13.5% 4.0% 
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Lysine 1.10 0.10 5.4% 4.5% 
Maleic acid 0.81 0.20 16.3% 14.6% 
Malic acid 0.91 0.44 15.3% 11.4% 
Malonic acid/Hydroxypyruvic acid 1.05 0.52 10.7% 6.9% 
Methionine 1.12 0.19 9.2% 6.0% 
Methylmalonic acid 0.83 0.21 18.9% 13.0% 
Monoethyl malonic acid 1.04 0.72 11.6% 11.7% 
Myo-Inositol 0.82 0.29 26.2% 14.1% 
N-Acetylaspartylglutamic acid 1.59 0.19 32.5% 36.1% 
N-Acetyl-L-aspartic acid 0.85 0.24 17.4% 12.7% 
N-Acetyl-L-methionine 0.87 0.24 17.4% 7.0% 
NAD 0.76 0.37 39.9% 27.6% 
Niacinamide 0.62 0.07 18.0% 25.7% 
Nicotinamide N-oxide 1.05 0.75 23.3% 11.0% 
Ornithine 0.87 0.49 30.8% 6.3% 
Orotic acid 1.78 0.20 44.9% 39.8% 
Pantothenate 1.11 0.09 7.7% 1.3% 
Pantothenol 1.58 0.18 31.7% 35.8% 
Phenylalanine 1.14 0.05 8.0% 0.9% 
Phosphocholine 0.89 0.08 6.5% 3.0% 
Phosphodimethylethanolamine 0.96 0.67 11.8% 4.5% 
Phosphoethanolamine 0.89 0.12 8.6% 1.8% 
Phosphoric acid 0.86 0.38 26.0% 6.1% 
Proline 1.02 0.82 14.5% 2.1% 
Propionic acid 0.97 0.86 17.8% 23.4% 
Pyridine N-oxide glucuronide 1.37 0.20 17.5% 30.6% 
Pyroglutamic acid 1.24 0.13 1.9% 16.6% 
Pyruvaldehyde 0.80 0.17 14.7% 14.9% 
Pyruvate 1.05 0.13 3.0% 2.7% 
Sarcosine 1.07 0.64 21.7% 2.6% 
S-Carboxymethyl-L-cysteine 1.19 0.37 32.0% 11.5% 
Serine 3.06 0.00 16.0% 3.7% 
Serinyl-Valine/Valyl-Serine 1.54 0.18 29.1% 34.9% 
Spermine 1.81 0.21 47.4% 40.4% 
Succinate 0.90 0.35 15.7% 6.8% 
Succinylacetone 1.11 0.28 5.0% 14.4% 
Taurine 0.84 0.01 5.6% 3.1% 
Theanine 1.21 0.09 14.2% 4.9% 
Threonic acid 0.96 0.73 10.3% 12.1% 
Tryptophan 1.05 0.75 21.7% 15.7% 
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Tyrosine 1.24 0.06 14.3% 0.9% 
UDP-Acetylgalactosamine 0.92 0.75 22.6% 32.2% 
UDP-Acetylglucosamine 0.97 0.74 13.7% 9.0% 
UMP 0.83 0.22 13.6% 13.9% 
Uracil 1.56 0.18 30.0% 35.2% 
Urea 1.14 0.26 19.0% 5.9% 
Uridine 0.84 0.12 8.9% 10.6% 
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